var title_f21_0_21504="Examination of finger DIP joint flexion";
var content_f21_0_21504=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Examination of finger DIP joint flexion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 312px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Flexion of the distal interphalangeal (DIP) joint is evaluated independently of other finger movements.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_0_21504=[""].join("\n");
var outline_f21_0_21504=null;
var title_f21_0_21505="Nasopharyngeal swab";
var content_f21_0_21505=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F81502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F81502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Nasopharyngeal swab sampling for pertussis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_0_21505=[""].join("\n");
var outline_f21_0_21505=null;
var title_f21_0_21506="Upper endoscopy";
var content_f21_0_21506=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Upper endoscopy (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?21/0/21506/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/0/21506/contributors\" id=\"au6609\">",
"       David A Greenwald, MD, FASGE, FACG",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?21/0/21506/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/0/21506/contributors\" id=\"se6265\">",
"       Mark Feldman, MD, MACP, AGAF, FACG",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?21/0/21506/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/0/21506/contributors\" id=\"de2797\">",
"       Anne C Travis, MD, MSc, FACG",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?21/0/21506?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      ENDOSCOPY OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     An upper endoscopy, often referred to as endoscopy, EGD, or esophago-gastro-duodenoscopy, is a procedure that allows a physician to directly examine the upper part of the gastrointestinal (GI) tract, which includes the esophagus , the stomach, and the duodenum (the first section of the small intestine) (",
"     <a class=\"graphic graphic_figure graphicRef55616 \" href=\"UTD.htm?28/22/29024\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     The physician who performs the procedure, known as an endoscopist, has special training in using an endoscope to examine the upper GI system, looking for inflammation (redness, irritation), bleeding, ulcers, or tumors.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      REASONS FOR UPPER ENDOSCOPY",
"     </span>",
"    </p>",
"    <p>",
"     The most common reasons for upper endoscopy include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Unexplained discomfort in the upper abdomen.",
"      </li>",
"      <li>",
"       GERD or gastroesophageal reflux disease (often called heartburn). (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=see_link\">",
"        \"Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Persistent nausea and vomiting.",
"      </li>",
"      <li>",
"       Upper GI bleeding (vomiting blood or blood found in the stool that originated from the upper part of the GI tract). Bleeding can be treated during the endoscopy.",
"      </li>",
"      <li>",
"       Difficulty swallowing;",
"       <span class=\"nowrap\">",
"        food/liquids",
"       </span>",
"       getting stuck in the esophagus during swallowing. This may be caused by a narrowing (stricture) or tumor or because the esophagus is not contracting properly. If there is a stricture, it can often be dilated with special balloons or dilation tubes during the endoscopy.",
"      </li>",
"      <li>",
"       Abnormal or unclear findings on an upper GI x-ray, CT scan, or MRI.",
"      </li>",
"      <li>",
"       Removal of a foreign body (a swallowed object).",
"      </li>",
"      <li>",
"       To check healing or progress on previously found polyps (growths), tumors, or ulcers.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      ENDOSCOPY PREPARATION",
"     </span>",
"    </p>",
"    <p>",
"     You will be given specific instructions regarding how to prepare for the examination before the procedure. These instructions are designed to maximize your safety during and after the examination and to minimize possible complications. It is important to read the instructions ahead of time and follow them carefully. Do not hesitate to call the physician's office or the endoscopy facility if there are questions.",
"    </p>",
"    <p>",
"     You may be asked not to eat or drink anything for up to eight hours before the test. It is important for your stomach to be empty to allow the endoscopist to visualize the entire area and to decrease the possibility of food or fluid being vomited into the lungs while under sedation (called aspiration).",
"    </p>",
"    <p>",
"     You may be asked to adjust the dose of your medications (such as insulin) or to stop specific medications (such as blood thinning medications) temporarily before the examination. You should discuss your medications with your physician before your appointment for the endoscopy.",
"    </p>",
"    <p>",
"     You should arrange for a friend or family member to escort you home after the examination. Although you will be awake by the time you are discharged, the medications used for sedation may cause temporary changes in the reflexes and judgment and interfere with your ability to drive or make decisions (similar to the effects of alcohol).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      WHAT TO EXPECT DURING ENDOSCOPY",
"     </span>",
"    </p>",
"    <p>",
"     Prior to the endoscopy, the staff will review your medical and surgical history, including current medications. A physician will explain the procedure and ask you to sign consent. Before signing consent, you should understand all the benefits and risks of the procedure, and should have all of your questions answered.",
"    </p>",
"    <p>",
"     An intravenous line (a needle inserted into a vein in the hand or arm) will be inserted to deliver medications. You may be given a combination of a sedative (to help you relax), and a narcotic (to prevent discomfort).",
"    </p>",
"    <p>",
"     Although most patients are sedated for the examination, many tolerate the procedure well without any medication.",
"    </p>",
"    <p>",
"     Your vital signs (blood pressure, heart rate, and blood oxygen level) will be monitored before, during, and after the examination. The monitoring is not painful. Oxygen is often given during the procedure through a small tube that sits under the nose and is fitted around the ears. For safety reasons, dentures should be removed before the procedure.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      THE ENDOSCOPY PROCEDURE",
"     </span>",
"    </p>",
"    <p>",
"     The procedure typically takes between 10 and 20 minutes to complete. The endoscopy is performed while you lie on your left side. Sometimes the physician will give a medication to numb the throat (either a gargle or a spray). A plastic mouth guard is placed between the teeth to prevent damage to the teeth and endoscope.",
"    </p>",
"    <p>",
"     The endoscope (also called a gastroscope) is a flexible tube that is about the size of a finger. The endoscope has a lens and a light source that allows the endoscopist to see the inner lining of the upper GI tract, usually on a TV monitor. Most people have no difficulty swallowing the flexible gastroscope as a result of the sedating medications. Many people sleep during the test; others are very relaxed and generally not aware of the examination.",
"    </p>",
"    <p>",
"     An alternative procedure called transnasal endoscopy may be available in some facilities. This involves passing a very thin scope (about the size of a drinking straw) through the nose. You are not sedated but a medication is applied to the nose to prevent discomfort. A full examination can be performed with this instrument.",
"    </p>",
"    <p>",
"     The endoscopist may take tissue samples called biopsies. Obtaining biopsies is not painful. The endoscopist may also perform specific treatments (such as dilation, removal of polyps, treatment of bleeding), depending upon what is found during the examination. Air is gently introduced through the endoscope to open the esophagus, stomach, and intestine, allowing the endoscope to be passed through these areas and improving the endoscopist's ability to see completely. You may experience mild discomfort as air is pushed into the stomach and intestinal tract. This is not harmful; belching may relieve the sensation. The endoscope does not interfere with breathing. Taking slow, deep breaths during the procedure may help you to relax.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      RECOVERY FROM ENDOSCOPY",
"     </span>",
"    </p>",
"    <p>",
"     After the endoscopy, you will be observed for a period of time, generally less than one hour, while the sedative medication wears off. Some of the medicines commonly used cause some people to temporarily feel tired or have difficulty concentrating. You typically will be instructed not to drive and not to return to work for the balance of the day of the procedure.",
"    </p>",
"    <p>",
"     The most common discomfort after the examination is a feeling of bloating as a result of the air introduced during the examination. This usually resolves quickly. Some patients also have a mild sore throat. Most patients are able to eat shortly after the examination.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      ENDOSCOPY COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     Upper endoscopy is a safe procedure and complications are rare. The following is a list of some possible complications:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Aspiration (inhaling) of food or fluids into the lungs, the risk of which can be minimized by not eating or drinking for the recommended period of time before the examination.",
"      </li>",
"      <li>",
"       Reactions to the sedative medications are possible; the endoscopy team (doctors and nurses) will ask about previous medication allergies or reactions and about health problems such as heart, lung, kidney, or liver disease. Providing this information to the team ensures a safer examination.",
"      </li>",
"      <li>",
"       The medications may produce irritation in the vein at the site of the intravenous catheter. If redness, swelling, or discomfort occurs, you should call your endoscopist or primary care provider, or the number given by the nurse at discharge.",
"      </li>",
"      <li>",
"       Bleeding can occur from biopsies or the removal of polyps, although if bleeding occurs, it is usually minimal and stops quickly on its own or can be easily controlled.",
"      </li>",
"      <li>",
"       The endoscope can cause a tear or hole in the area being examined. This is a serious complication but fortunately occurs extremely rarely.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The following signs and symptoms should be reported immediately:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Severe abdominal pain (more than gas cramps)",
"      </li>",
"      <li>",
"       A firm, distended abdomen",
"      </li>",
"      <li>",
"       Vomiting",
"      </li>",
"      <li>",
"       Any temperature elevation",
"      </li>",
"      <li>",
"       Difficulty swallowing or severe throat pain",
"      </li>",
"      <li>",
"       A crunching feeling under the skin of the neck",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      AFTER UPPER ENDOSCOPY",
"     </span>",
"    </p>",
"    <p>",
"     Most patients tolerate endoscopy very well and feel fine afterwards. Some fatigue is common after the examination, and you should plan to take it easy and relax the rest of the day.",
"    </p>",
"    <p>",
"     The endoscopist can describe the result of the examination before you leave the endoscopy facility. If biopsies have been taken or polyps removed, you should call for results at a time specified by the endoscopist, typically within one to two weeks.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1784863816\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3356627\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=see_link\">",
"      Patient information: Upper endoscopy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/53/5971?source=see_link\">",
"      Patient information: Peptic ulcers (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/29/13778?source=see_link\">",
"      Patient information: Barrett's esophagus (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/50/20258?source=see_link\">",
"      Patient information: Achalasia (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/60/24515?source=see_link\">",
"      Patient information: GI bleed (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/60/8130?source=see_link\">",
"      Patient information: Gastroparesis (delayed gastric emptying) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/17/9491?source=see_link\">",
"      Patient information: Esophageal cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/46/1763?source=see_link\">",
"      Patient information: Gastritis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/54/41826?source=see_link\">",
"      Patient information: Angiodysplasia of the GI tract (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/19/10546?source=see_link\">",
"      Patient information: Esophageal stricture (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/28/32195?source=see_link\">",
"      Patient information: Stomach cancer (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3356728\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=see_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41367?source=see_link\">",
"      Antibiotic prophylaxis for gastrointestinal endoscopic procedures",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13750?source=see_link\">",
"      Autofluorescence endoscopy for Barrett's esophagus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/10/6312?source=see_link\">",
"      Endoscope disinfection",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14089?source=see_link\">",
"      Endoscopic diagnosis of inflammatory bowel disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/53/39766?source=see_link\">",
"      Endoscopic management of pseudocysts of the pancreas: Efficacy and complications",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27655?source=see_link\">",
"      Endoscopic management of pseudocysts of the pancreas: Technique",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=see_link\">",
"      Endoscopic procedures in patients with disorders of hemostasis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4248?source=see_link\">",
"      Magnification endoscopy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24649?source=see_link\">",
"      Overview of deep small bowel enteroscopy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24936?source=see_link\">",
"      Overview of procedural sedation for gastrointestinal endoscopy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43049?source=see_link\">",
"      Alternatives and adjuncts to moderate procedural sedation for gastrointestinal endoscopy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42694?source=see_link\">",
"      Sedation-free gastrointestinal endoscopy",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Society of Gastrointestinal Endoscopy",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.askasge.org/\">",
"      www.askasge.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://digestive.niddk.nih.gov/ddiseases/pubs/upperendoscopy/index.htm\">",
"      file://digestive.niddk.nih.gov/ddiseases/pubs/upperendoscopy/index.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     The author would like to acknowledge Maryanne Barretti, RN, Nurse Manager of Endoscopy at Mount Sinai Hospital, for her advice and critical input.",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?21/0/21506/abstract/1-6\">",
"      1-6",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?21/0/21506?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     Carpenter-Aquino A. SGNA Gastroenterology Nursing, A Core Curriculum, 4th ed, 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21506/abstract/2\">",
"      Kielty LA. An investigation into the information received by patients undergoing a gastroscopy in a large teaching hospital in Ireland. Gastroenterol Nurs 2008; 31:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21506/abstract/3\">",
"      Ford AC, Moayyedi P. Current guidelines for dyspepsia management. Dig Dis 2008; 26:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21506/abstract/4\">",
"      Cho S, Arya N, Swan K, et al. Unsedated transnasal endoscopy: a Canadian experience in daily practice. Can J Gastroenterol 2008; 22:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21506/abstract/5\">",
"      Standards of Practice Committee, Zuckerman MJ, Shen B, et al. Informed consent for GI endoscopy. Gastrointest Endosc 2007; 66:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21506/abstract/6\">",
"      Lazzaroni M, Bianchi Porro G. Preparation, premedication, and surveillance. Endoscopy 2005; 37:101.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f21_0_21506=[""].join("\n");
var outline_f21_0_21506=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           ENDOSCOPY OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           REASONS FOR UPPER ENDOSCOPY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           ENDOSCOPY PREPARATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           WHAT TO EXPECT DURING ENDOSCOPY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           THE ENDOSCOPY PROCEDURE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           RECOVERY FROM ENDOSCOPY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           ENDOSCOPY COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           AFTER UPPER ENDOSCOPY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/22/29024\" title=\"figure 1\">",
"           Upper GI anatomy PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f21_0_21507="Pneumococcus in sputum";
var content_f21_0_21507=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75924&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75924&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sputum from a patient with pneumococcal pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of sputum (x1000) shows abundant inflammatory cells and gram-positive diplococci; Streptococcus pneumoniae was identified from this specimen by culture and by the optochin disk test.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_0_21507=[""].join("\n");
var outline_f21_0_21507=null;
var title_f21_0_21508="Early transition tutorial";
var content_f21_0_21508=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 526px\">",
"   <div class=\"ttl\">",
"    Early transition (counterclockwise rotation)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 506px; height: 125px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tall R waves are seen earlier than normal across the precordium, in lead V2 in this example.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_0_21508=[""].join("\n");
var outline_f21_0_21508=null;
var title_f21_0_21509="Presyrinx";
var content_f21_0_21509=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F75789&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F75789&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Four-year-old girl with Chiari I malformation and previous incomplete decompressive surgery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 419px; height: 586px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) T1-weighted sagittal MRI of the cervical and thoracic spine before repeat surgery shows herniation of the cerebellar tonsils to C2-3, hypointensity and frank cavitation from C6-T1 (syrinx), and indistinct parenchymal hypointensity from C2-5 and T2-3 (presyrinx).",
"    <br>",
"     (B) T2-weighted sagittal MRI of the cervical and thoracic spine before repeat surgery shows T2 prolongation in the areas of the syrinx and presyrinx.",
"     <br>",
"      (C) T2-weighted sagittal MRI of the cervical and thoracic spine after decompression shows decreased size of the large cervical cord syrinx (C6-7) and complete resolution of the presyrinx.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: Goh S, Bottrell CL, Aiken AH, et al. Presyrinx in children with Chiari malformations. Neurology 2008; 71:351. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_0_21509=[""].join("\n");
var outline_f21_0_21509=null;
var title_f21_0_21510="Synovial tissue in RA";
var content_f21_0_21510=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F66931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F66931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Synovial tissue in rheumatoid arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 416px; height: 290px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photomicrograph of synovial tissue in RA showing prominent hyperplasia of the synovial lining layer. The inflammatory infiltrate in the sublining is comprised predominantly of lymphocytes, plasma cells, and macrophages (hematoxylin and eosin).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ellen M Gravallese, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_0_21510=[""].join("\n");
var outline_f21_0_21510=null;
var title_f21_0_21511="Fluorescence bronchoscopy";
var content_f21_0_21511=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fluorescence bronchoscopy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/0/21511/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/0/21511/contributors\">",
"     Anindo K Banerjee, PhD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/0/21511/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/0/21511/contributors\">",
"     Praveen N Mathur, MB, BS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/0/21511/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/0/21511/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/0/21511/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Squamous cell carcinoma of the bronchus develops from carcinogen-exposed bronchial epithelium. It probably progresses through a series of preinvasive lesions (metaplasia, dysplasia, carcinoma in situ), followed by microinvasive carcinoma and then fully invasive carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fluorescence bronchoscopy has been developed to identify preinvasive lesions. The hope is that identification and treatment of such lesions may improve the outcome from squamous cell carcinoma of the bronchus [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Technical aspects of fluorescence bronchoscopy and its clinical role are reviewed here. Lung cancer screening, evaluation, and treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28586?source=see_link\">",
"     \"Screening for lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13273?source=see_link\">",
"     \"Overview of the initial evaluation, treatment and prognosis of lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BIOLOGICAL RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been known since the early part of the last century that tissues fluoresce when exposed to light of a suitable wavelength and that the fluorescence is altered by infiltrating tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. It was hypothesized that such differences in fluorescence might help detect tumors in the airways, but initial attempts were unsuccessful because either the intensity of fluorescence was too low to be detected with the naked eye or the fluorescence was obscured by light reflected from the bronchoscope's excitation beam. Photosensitizing fluorescent compounds (eg, hematoporphyrin derivatives) were used to increase the intensity of the fluorescence, but this approach was limited by skin photosensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. As a result of these limitations, interest in fluorescence bronchoscopy diminished.",
"   </p>",
"   <p>",
"    Technological advances in image acquisition and processing have improved the detection of subtle differences in fluorescence without the use of a fluorophore. This has renewed interest in fluorescence bronchoscopy. Dysplasia, carcinoma in situ, and microinvasive carcinoma exhibit much weaker green fluorescence and slightly weaker red fluorescence than normal tissues, when illuminated by light with a wavelength of 380 to 440 nm (blue spectrum) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/9\">",
"     9",
"    </a>",
"    ]. The reasons for the differences in fluorescence are not well understood, but may be due to increased epithelial thickness, increased blood flow,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a reduced concentration of fluorophores in abnormal tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Advances in fluorescence bronchoscopy have been matched by improvements in conventional white light bronchoscopy. Developments in optics and image processing (eg, optical coherence tomography, narrow band imaging, high magnification bronchoscopy) have improved optical resolution and characterization of the bronchial mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/12\">",
"     12",
"    </a>",
"    ]. Tissue microstructure, epithelial thickness, vessel density, and microvascular network changes can now be determined, allowing minimally invasive assessment of bronchial epithelial lesions. These advances, combined with fluorescence imaging, have the potential to improve the detection and characterization of bronchial preinvasive lesions and early carcinomas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INSTRUMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most fluorescence bronchoscopy systems use autofluorescence, rather than induced fluorescence. Autofluorescence refers to the fluorescence of tissues when exposed to light of a suitable wavelength. In contrast, induced fluorescence refers to tissue fluorescence that is induced by a photosensitizing compound.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     LIFE devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first autofluorescence bronchoscopy system that was commercially available was the Light-Induced Fluorescence Endoscopy (LIFE) device (Xillix Technologies Corporation, Vancouver, Canada) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. This device illuminated the bronchial tree with blue light from a helium-cadmium laser and collected autofluorescence images via its imaging bundles. The red and green wavelengths of the autofluorescence image were filtered and amplified by image-intensifying cameras. Their relative intensities were measured and this information was used to display a computer-enhanced image delineating abnormal areas of fluorescence.",
"   </p>",
"   <p>",
"    The LIFE device has been superseded by the Onco-LIFE device, which is also called Pinpoint (Novadaq Technologies, Toronto, Canada) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/15\">",
"     15",
"    </a>",
"    ]. This device uses a filtered blue light source to generate green autofluorescence images and a red light source to obtain red reflectance images. The images are analyzed and assigned contrasting colors, which are displayed as a single real-time image on a video monitor. The green autofluorescence is normalized by the red reflectance, which enhances the contrast between normal and abnormal tissue. This reduces the rate of false positive results. Abnormal tissue appears brown-red on a green background (",
"    <a class=\"graphic graphic_table graphicRef54332 \" href=\"UTD.htm?8/3/8252\">",
"     table 1",
"    </a>",
"    ). The relative differences in intensity between the blue light-induced green autofluorescence and the red light-induced red reflectance can be displayed numerically, providing some quantification of the fluorescence changes.",
"   </p>",
"   <p>",
"    Autofluorescence and white light bronchoscopy are typically performed during the same session. The LIFE device required separate light sources for each, but the Onco-LIFE device can switch between autofluorescence and white light bronchoscopy using the same device and light source.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Karl Storz device",
"    </span>",
"    &nbsp;&mdash;&nbsp;Karl Storz Gmbh &amp; Co. (Tuttlingen, Germany) makes an autofluorescence bronchoscopy system that utilizes a conventional xenon light source and an optical filter that is fitted to the eyepiece of the bronchoscope [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The light source illuminates the bronchial tree with either two bands of blue light (autofluorescence mode) or white light (conventional white light mode). The type of illumination is controlled by a switch on the bronchoscope, allowing autofluorescence and conventional white light bronchoscopy to be easily performed during the same session.",
"     </li>",
"     <li>",
"      The optical filter transmits the red and green wavelengths reflected by the issue, as well as some of the excitation wavelength. This facilitates visualization in areas of low fluorescence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The images are viewed through the eyepiece of the bronchoscope or displayed on a monitor using a charge-coupled device (CCD) camera. Abnormal tissue appears brown-purple on a blue-grey background (",
"    <a class=\"graphic graphic_table graphicRef54332 \" href=\"UTD.htm?8/3/8252\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A potential advantage of the Karl Storz bronchoscope is that less time is required to complete a procedure, compared to other devices [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/17\">",
"     17",
"    </a>",
"    ]. In addition, the Karl Storz system can detect both autofluorescence and induced fluorescence [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Autofluorescence is more common because it is simple, easy to perform, and avoids light sensitization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other devices that are available for fluorescence bronchoscopy are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef54332 \" href=\"UTD.htm?8/3/8252\">",
"     table 1",
"    </a>",
"    ). They include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The SAFE-1000 (Pentax, Tokyo, Japan) has been superseded by the SAFE-3000 (Pentax, Tokyo, Japan), a device that uses a xenon blue light source and a single CCD camera [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/20\">",
"       20",
"      </a>",
"      ]. Autofluorescence images are generated by digital processing and can be viewed either simultaneously with white light images (ie, side by side) or superimposed on white light images. Abnormal tissue appears red-purple on a blue-green background.",
"     </li>",
"     <li>",
"      The Wolf system (Richard Wolf GmbH, Knittlingen, Germany) uses a filtered 300W Xenon lamp and filters to obtain the autofluorescence images [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/21\">",
"       21",
"      </a>",
"      ]. Abnormal tissue appears purple on a blue-grey background.",
"     </li>",
"     <li>",
"      The Olympus LUCERA system (Olympus, Tokyo, Japan) uses a Xenon lamp with a rotating filter wheel to filter blue and green light as the excitation beam. Autofluorescence generated by the blue light is filtered, detected by the CCD camera, and displayed on the blue channel [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/22\">",
"       22",
"      </a>",
"      ]. Reflectance from the green light is filtered, detected by the CCD camera, and displayed on the red and blue channels of the monitor. Abnormal tissue appears magenta on a green background.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL EVIDENCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Diagnostic characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most clinical studies that evaluated the diagnostic characteristics of autofluorescence bronchoscopy used the LIFE autofluorescence bronchoscope [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/13,14,23\">",
"     13,14,23",
"    </a>",
"    ]. However, the Karl Storz device has been used with similar results [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/17,24,25\">",
"     17,24,25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Instruments'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Most studies performed conventional white light bronchoscopy first, followed by autofluorescence bronchoscopy during the same session. Biopsies were taken from areas that appeared abnormal during either type of bronchoscopy. Control biopsies were taken from areas that appeared bronchoscopically normal. The ability of each bronchoscopic modality to distinguish abnormal epithelium (ie, dysplasia, carcinoma in situ, microinvasive carcinoma, or invasive carcinoma) from normal epithelium was determined by histological examination of the biopsy specimens.",
"   </p>",
"   <p>",
"    Studies performed in this way have been subjected to the following criticisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Observations during white light bronchoscopy may have biased the subsequent autofluorescence bronchoscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. This was evaluated in a trial that failed to confirm the bias. The trial randomly assigned 55 patients with suspected lung cancer to undergo either white light followed by autofluorescence bronchoscopy, or autofluorescence followed by white light bronchoscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/26\">",
"       26",
"      </a>",
"      ]. The sequence of the procedures did not affect the results.",
"     </li>",
"     <li>",
"      Estimates of the sensitivity of autofluorescence bronchoscopy may have been exaggerated in studies that calculated sensitivity from the number of biopsies that revealed abnormal histology, rather than the number of discrete lesions detected, since more than one biopsy may have been taken from a lesion [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/23,24\">",
"       23,24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Estimates of the sensitivity of autofluorescence may have been imprecise because the number of preinvasive lesions within the visible bronchial tree cannot be accurately determined by control biopsies. In a study that addressed this possibility, autofluorescence bronchoscopy was performed prior to lobectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/27\">",
"       27",
"      </a>",
"      ]. The bronchial tree was dissected from the lobectomy specimen and the number of preinvasive lesions was determined. Autofluorescence bronchoscopy detected approximately 50 percent of the preinvasive lesions. This suggests that the true sensitivity is lower than that estimated by studies that used control biopsies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Sensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is general agreement that autofluorescence bronchoscopy, combined with conventional white light bronchoscopy, improves the detection of airway preinvasive lesions compared to conventional white light bronchoscopy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/28\">",
"     28",
"    </a>",
"    ]. In other words, combined white light and autofluorescence bronchoscopy is more sensitive than white light bronchoscopy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/13-17,20-26,29\">",
"     13-17,20-26,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The degree to which combined white light and autofluorescence bronchoscopy is more sensitive than conventional white light bronchoscopy alone appears to vary according to the histological grade of the preinvasive lesion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High grade preinvasive lesions (moderate to severe dysplasia, carcinoma in situ) are detected 1.2 to 6.3 times (mean 2.7 times) more often with combined white light and autofluorescence bronchoscopy than with conventional white light bronchoscopy alone [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/15,23\">",
"       15,23",
"      </a>",
"      ]. This equates to a sensitivity of 86 percent for combined white light and autofluorescence bronchoscopy and a sensitivity of 46 percent for conventional white light bronchoscopy alone.",
"     </li>",
"     <li>",
"      Low grade preinvasive lesions (squamous metaplasia, mild dysplasia) are detected with similar sensitivity by conventional white light bronchoscopy alone and combined white light and autofluorescence bronchoscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/30,31\">",
"       30,31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When high grade preinvasive lesions and invasive carcinoma are considered together, the sensitivity improves 1.2 to 3.7 times (mean 1.9 times) with combined white light and autofluorescence bronchoscopy, compared to conventional white light bronchoscopy alone [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/15,23\">",
"       15,23",
"      </a>",
"      ]. This equates to a sensitivity of 85 percent for combined white light and autofluorescence bronchoscopy and a sensitivity of 58 percent for conventional white light bronchoscopy alone. This relative difference is smaller than that described above for high grade preinvasive lesions because conventional white light bronchoscopy is better at detecting invasive carcinomas than preinvasive lesions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although autofluorescence bronchoscopy is effective at distinguishing abnormal from normal airway epithelium, it is incapable of predicting the histologic diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/15,23\">",
"     15,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Positive predictive value",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined white light and autofluorescence bronchoscopy is better at detecting airway lesions than conventional white light bronchoscopy alone, but it is also more likely to give false positive results [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/15\">",
"     15",
"    </a>",
"    ]. In a study that determined the proportion of biopsies from areas of abnormal autofluorescence that contained abnormal histology, the positive predictive value was only 33 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/23\">",
"     23",
"    </a>",
"    ]. A limitation of predictive values is that they are highly influenced by the prevalence of the disorder in the population studied. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10054?source=see_link\">",
"     \"Evaluating diagnostic tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is possible that some lesions, considered false positive results on the basis of histology, actually represent abnormal epithelium that is so early in its development that it still appears histologically normal. Supporting this possibility, a study found that 50 percent of the lesions that exhibited abnormal autofluorescence, but normal histology, had molecular abnormalities that were similar to preinvasive lesions and invasive carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Clinical outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is evidence that the poor prognosis of lung cancer is partially attributable to the advanced",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inoperable stage at which most patients present [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/33-37\">",
"     33-37",
"    </a>",
"    ]. The goal of autofluorescence bronchoscopy is to improve clinical outcomes by detecting lung cancers at an early stage, when surgery provides the best chance of cure.",
"   </p>",
"   <p>",
"    The impact of autofluorescence bronchoscopy on clinical outcomes (eg, mortality) is unknown because it has not been well studied. However, it has been hypothesized that autofluorescence bronchoscopy may improve survival from squamous cell carcinoma of the bronchus by prompting an intervention before the lesion has invaded or metastasized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no universally accepted indications for autofluorescence bronchoscopy. Suggested indications include the evaluation of patients who have high grade sputum atypia but no radiological abnormalities, surveillance of patients with previously detected high grade preinvasive lesions who do not have evidence of invasive carcinoma, and planning endobronchial therapy for patients who have early invasive lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Sputum atypia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autofluorescence bronchoscopy may be helpful in the evaluation of patients who have high grade sputum atypia with normal radiological imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/28\">",
"     28",
"    </a>",
"    ]. The goal is to identify the culprit lesion, which may be difficult with conventional white light bronchoscopy alone because abnormalities are often subtle and can occur over a wide area of the tracheobronchial tree (especially among individuals who have smoked heavily or have already had an invasive lung cancer) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ability of autofluorescence bronchoscopy to detect the culprit lesion was illustrated by a study of 92 smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/29\">",
"     29",
"    </a>",
"    ]. In the subgroup of patients who had abnormal sputum cytology and normal radiographical imaging, combined white light and autofluorescence bronchoscopy detected lung cancer 2.8 times more often than conventional white light bronchoscopy alone (11.1 versus 4 percent).",
"   </p>",
"   <p>",
"    Autofluorescence bronchoscopy may also identify individuals who are at increased risk of developing carcinoma. In a study of 46 patients with sputum atypia or previous history of aerodigestive carcinoma, the number of areas within the bronchial tree that had abnormal autofluorescence was directly related to the risk of developing squamous cell carcinoma over the next four years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;High grade preinvasive lesions (ie, moderate to severe dysplasia, carcinoma in situ) are sometimes treated endoscopically or surgically by clinicians who believe that such lesions are at significant risk of malignant change [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]. We believe that high grade preinvasive lesions can be followed bronchoscopically, with prompt intervention if there is confirmed progression to invasive carcinoma. Combined white light bronchoscopy and autofluorescence bronchoscopy is the preferred bronchoscopic modality, if available. This approach is supported by clinical practice guidelines from the American College of Chest Physicians [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The strategy of following patients who have high grade preinvasive lesions bronchoscopically , rather than treating them endoscopically or surgically, is based upon two concerns [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presumption that all high grade preinvasive lesions will inevitably develop into malignancy may be incorrect. Such progression has been confirmed histologically in fewer than 100 lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/43,45,47-49\">",
"       43,45,47-49",
"      </a>",
"      ]. In addition, a review of the literature found that only one out of three high grade preinvasive lesions likely progressed to invasive carcinoma, which was equal to the rate of regression to normal epithelium [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The efficacy of treating dysplasia and carcinoma in situ is uncertain. There is evidence that up to 67 percent of lesions may progress to invasive carcinoma despite therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/42,43,49,50\">",
"       42,43,49,50",
"      </a>",
"      ]. There is also a risk that new lesions may develop elsewhere in the bronchial tree [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/42,51\">",
"       42,51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Planning therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autofluorescence bronchoscopy may be helpful in the evaluation of patients with invasive carcinoma who are being considered for curative endobronchial or surgical treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/28\">",
"     28",
"    </a>",
"    ]. The purpose is to determine the extent of the abnormality and to look for other lesions.",
"   </p>",
"   <p>",
"    Findings during autofluorescence bronchoscopy may affect which therapy is selected and how it will be performed. As an example, accurate delineation of the extent of the carcinoma is required for photodynamic therapy, which should only be performed if all of the margins of the lesion are visible with autofluorescence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37749?source=see_link\">",
"     \"Photodynamic therapy of lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening current and former smokers for lung cancer is a controversial topic and an area of active investigation. It is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28586?source=see_link\">",
"     \"Screening for lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The combination of chest computed tomography (CT) plus fluorescence bronchoscopy is one method of lung cancer screening that has been investigated. The rationale for this approach is that chest CT identifies parenchymal nodules but not central airway lesions, whereas fluorescence bronchoscopy identifies central airway lesions but not parenchymal nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/52\">",
"     52",
"    </a>",
"    ]. The effectiveness of this approach in the detection of small early carcinomas has been confirmed in three clinical studies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21511/abstract/51-53\">",
"     51-53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fluorescence bronchoscopy was developed to detect preinvasive lesions (metaplasia, dysplasia, carcinoma in situ), with the hope that the identification and treatment of such lesions may improve the outcome from squamous cell carcinoma of the bronchus. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most fluorescence bronchoscopy systems use autofluorescence, rather than induced fluorescence. Autofluorescence bronchoscopy is the focus of this review. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Instruments'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Combined white light bronchoscopy and autofluorescence bronchoscopy detects abnormal airway lesions with greater sensitivity than conventional white light bronchoscopy alone. This includes metaplasia, dysplasia, carcinoma-in-situ, microinvasive carcinoma, and invasive carcinoma of the bronchus. The improvement in the sensitivity of lesion detection is greatest for high-grade preinvasive lesions (moderate to severe dysplasia, carcinoma-in-situ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnostic characteristics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An important limitation of autofluorescence bronchoscopy is that false positive results are common. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnostic characteristics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The impact of autofluorescence bronchoscopy on clinical outcomes, such as mortality, is unknown because it has not been well studied. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no universally accepted indications for autofluorescence bronchoscopy. However, suggested indications include the evaluation of patients who have high grade sputum atypia but no radiological abnormalities, surveillance of patients with previously detected high grade preinvasive lesions who do not have evidence of invasive carcinoma, and planning endobronchial therapy for patients who have early invasive lung cancer. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/1\">",
"      Hirsch FR, Franklin WA, Gazdar AF, Bunn PA Jr. Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. Clin Cancer Res 2001; 7:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/2\">",
"      Banerjee AK, Rabbitts PH, George J. Lung cancer . 3: Fluorescence bronchoscopy: clinical dilemmas and research opportunities. Thorax 2003; 58:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/3\">",
"      Bolliger CT, Mathur PN, Beamis JF, et al. ERS/ATS statement on interventional pulmonology. European Respiratory Society/American Thoracic Society. Eur Respir J 2002; 19:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/4\">",
"      Ernst A, Silvestri GA, Johnstone D, American College of Chest Physicians. Interventional pulmonary procedures: Guidelines from the American College of Chest Physicians. Chest 2003; 123:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/5\">",
"      Sutro, CJ, Burman, MS. Examination of pathologic tissue by filtered ultraviolet radiation. Arch Pathol 1933; 16:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/6\">",
"      Herly, L. Studies in selective differentiation of tissues by means of filtered ultraviolet light. Cancer Res 1943; 1:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/7\">",
"      LIPSON RL, BALDES EJ. The photodynamic properties of a particular hematoporphyrin derivative. Arch Dermatol 1960; 82:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/8\">",
"      Kato H, Cortese DA. Early detection of lung cancer by means of hematoporphyrin derivative fluorescence and laser photoradiation. Clin Chest Med 1985; 6:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/9\">",
"      Hung J, Lam S, LeRiche JC, Palcic B. Autofluorescence of normal and malignant bronchial tissue. Lasers Surg Med 1991; 11:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/10\">",
"      Qu, J, MacAulay, C, Lam, S, et al. Laser induced fluorescence spectroscopy at endoscopy: Tissue optics; Monte Carlo modeling and in vivo measurements. Optical Eng 1995; 34:3334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/11\">",
"      Qu, J, MacAulay, C, Lam, S, Palcic, B. Mechanisms of ratio fluorescence imaging of diseased tissue. Society of Photo-optical Instrumentation Engineers 1995; 2387:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/12\">",
"      McWilliams A, Lam B, Sutedja T. Early proximal lung cancer diagnosis and treatment. Eur Respir J 2009; 33:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/13\">",
"      Lam S, MacAulay C, Hung J, et al. Detection of dysplasia and carcinoma in situ with a lung imaging fluorescence endoscope device. J Thorac Cardiovasc Surg 1993; 105:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/14\">",
"      Lam S, Macaulay C, Leriche JC, et al. Early localization of bronchogenic carcinoma. Diagn Ther Endosc 1994; 1:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/15\">",
"      Edell E, Lam S, Pass H, et al. Detection and localization of intraepithelial neoplasia and invasive carcinoma using fluorescence-reflectance bronchoscopy: an international, multicenter clinical trial. J Thorac Oncol 2009; 4:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/16\">",
"      Leonhard M. New incoherent autofluorescence/fluorescence system for early detection of lung cancer. Diagn Ther Endosc 1999; 5:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/17\">",
"      Herth FJ, Ernst A, Becker HD. Autofluorescence bronchoscopy--a comparison of two systems (LIFE and D-Light). Respiration 2003; 70:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/18\">",
"      Baumgartner R, Huber RM, Schulz H, et al. Inhalation of 5-aminolevulinic acid: a new technique for fluorescence detection of early stage lung cancer. J Photochem Photobiol B 1996; 36:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/19\">",
"      Stepp, H, Baumgartner, R, Betz, CH, et al. New developments in fluorescence detection of ALA-induced Protoporphyrin IX for cancer detection. Society of Photo-optical Instrumentation Engineers 1997; 3197:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/20\">",
"      Ikeda N, Honda H, Hayashi A, et al. Early detection of bronchial lesions using newly developed videoendoscopy-based autofluorescence bronchoscopy. Lung Cancer 2006; 52:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/21\">",
"      Goujon D, Zellweger M, Radu A, et al. In vivo autofluorescence imaging of early cancers in the human tracheobronchial tree with a spectrally optimized system. J Biomed Opt 2003; 8:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/22\">",
"      Chiyo M, Shibuya K, Hoshino H, et al. Effective detection of bronchial preinvasive lesions by a new autofluorescence imaging bronchovideoscope system. Lung Cancer 2005; 48:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/23\">",
"      Lam S, Kennedy T, Unger M, et al. Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscopy. Chest 1998; 113:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/24\">",
"      H&auml;u&szlig;inger K, Stanzel F, Huber RM, et al. Autofluorescence Detection of Bronchial Tumors With the D-Light/AF. Diagn Ther Endosc 1999; 5:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/25\">",
"      Venmans, BJ, van der Linden, H, van Boxem, TJ, et al. Early detection of preinvasive lesions in high-risk patients: A comparison of conventional flexible and fluorescence bronchoscopy. J Bronchol 1998; 5:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/26\">",
"      Hirsch FR, Prindiville SA, Miller YE, et al. Fluorescence versus white-light bronchoscopy for detection of preneoplastic lesions: a randomized study. J Natl Cancer Inst 2001; 93:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/27\">",
"      Ikeda N, Hiyoshi T, Kakihana M, et al. Histopathological evaluation of fluorescence bronchoscopy using resected lungs in cases of lung cancer. Lung Cancer 2003; 41:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/28\">",
"      Kennedy TC, McWilliams A, Edell E, et al. Bronchial intraepithelial neoplasia/early central airways lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132:221S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/29\">",
"      H&auml;ussinger K, Becker H, Stanzel F, et al. Autofluorescence bronchoscopy with white light bronchoscopy compared with white light bronchoscopy alone for the detection of precancerous lesions: a European randomised controlled multicentre trial. Thorax 2005; 60:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/30\">",
"      Kurie JM, Lee JS, Morice RC, et al. Autofluorescence bronchoscopy in the detection of squamous metaplasia and dysplasia in current and former smokers. J Natl Cancer Inst 1998; 90:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/31\">",
"      O'Neil KM, Johnson BE. Lights flicker on fluorescence bronchoscopy in patients at risk for lung cancer. J Natl Cancer Inst 1998; 90:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/32\">",
"      Helfritzsch H, Junker K, Bartel M, Scheele J. Differentiation of positive autofluorescence bronchoscopy findings by comparative genomic hybridization. Oncol Rep 2002; 9:697.",
"     </a>",
"    </li>",
"    <li>",
"     National Lung Cancer Audit Report 2006. The Information Centre for Health and Social Care. Leeds, UK.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/34\">",
"      Imperatori A, Harrison RN, Leitch DN, et al. Lung cancer in Teesside (UK) and Varese (Italy): a comparison of management and survival. Thorax 2006; 61:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/35\">",
"      Groome PA, Bolejack V, Crowley JJ, et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007; 2:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/36\">",
"      Pearson FG. Current status of surgical resection for lung cancer. Chest 1994; 106:337S.",
"     </a>",
"    </li>",
"    <li>",
"     Spiro SG. Lung Tumours. In: Respiratory Medicine, Brewis RA, Gibson GJ, Geddes DM (Eds), Bailliere Tindall, 1990. p.832-79.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/38\">",
"      AUERBACH O, FORMAN JB, GERE JB, et al. Changes in the bronchial epithelium in relation to smoking and cancer of the lung; a report of progress. N Engl J Med 1957; 256:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/39\">",
"      Woolner LB, Fontana RS, Cortese DA, et al. Roentgenographically occult lung cancer: pathologic findings and frequency of multicentricity during a 10-year period. Mayo Clin Proc 1984; 59:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/40\">",
"      Pasic A, Vonk-Noordegraaf A, Risse EK, et al. Multiple suspicious lesions detected by autofluorescence bronchoscopy predict malignant development in the bronchial mucosa in high risk patients. Lung Cancer 2003; 41:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/41\">",
"      Bota S, Auliac JB, Paris C, et al. Follow-up of bronchial precancerous lesions and carcinoma in situ using fluorescence endoscopy. Am J Respir Crit Care Med 2001; 164:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/42\">",
"      Deygas N, Froudarakis M, Ozenne G, Vergnon JM. Cryotherapy in early superficial bronchogenic carcinoma. Chest 2001; 120:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/43\">",
"      Venmans BJ, van Boxem TJ, Smit EF, et al. Outcome of bronchial carcinoma in situ. Chest 2000; 117:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/44\">",
"      Cortese DA, Edell ES, Kinsey JH. Photodynamic therapy for early stage squamous cell carcinoma of the lung. Mayo Clin Proc 1997; 72:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/45\">",
"      Breuer RH, Pasic A, Smit EF, et al. The natural course of preneoplastic lesions in bronchial epithelium. Clin Cancer Res 2005; 11:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/46\">",
"      Banerjee AK, Rabbitts PH, George PJ. Are all high-grade preinvasive lesions premalignant, and should they all be treated? Am J Respir Crit Care Med 2002; 165:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/47\">",
"      Satoh Y, Ishikawa Y, Nakagawa K, et al. A follow-up study of progression from dysplasia to squamous cell carcinoma with immunohistochemical examination of p53 protein overexpression in the bronchi of ex-chromate workers. Br J Cancer 1997; 75:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/48\">",
"      Thiberville L, Payne P, Vielkinds J, et al. Evidence of cumulative gene losses with progression of premalignant epithelial lesions to carcinoma of the bronchus. Cancer Res 1995; 55:5133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/49\">",
"      Banerjee AK. Preinvasive lesions of the bronchus. J Thorac Oncol 2009; 4:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/50\">",
"      Moro-Sibilot D, Fievet F, Jeanmart M, et al. Clinical prognostic indicators of high-grade pre-invasive bronchial lesions. Eur Respir J 2004; 24:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/51\">",
"      Jeremy George P, Banerjee AK, Read CA, et al. Surveillance for the detection of early lung cancer in patients with bronchial dysplasia. Thorax 2007; 62:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/52\">",
"      McWilliams AM, Mayo JR, Ahn MI, et al. Lung cancer screening using multi-slice thin-section computed tomography and autofluorescence bronchoscopy. J Thorac Oncol 2006; 1:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21511/abstract/53\">",
"      Loewen G, Natarajan N, Tan D, et al. Autofluorescence bronchoscopy for lung cancer surveillance based on risk assessment. Thorax 2007; 62:335.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4409 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-C801F8800B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_0_21511=[""].join("\n");
var outline_f21_0_21511=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BIOLOGICAL RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INSTRUMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      LIFE devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Karl Storz device",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL EVIDENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Diagnostic characteristics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Sensitivity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Positive predictive value",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Clinical outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Sputum atypia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Surveillance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Planning therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4409\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4409|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/3/8252\" title=\"table 1\">",
"      Fluorescence bronchoscopes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10054?source=related_link\">",
"      Evaluating diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13273?source=related_link\">",
"      Overview of the initial evaluation, treatment and prognosis of lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37749?source=related_link\">",
"      Photodynamic therapy of lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28586?source=related_link\">",
"      Screening for lung cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_0_21512="Neonatal pneumonia";
var content_f21_0_21512=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neonatal pneumonia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/0/21512/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/0/21512/contributors\">",
"     Michael E Speer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/0/21512/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/0/21512/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/0/21512/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/0/21512/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/0/21512/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/0/21512/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumonia is an important cause of neonatal infection and accounts for significant morbidity and mortality, especially in developing countries [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In these countries, the World Health Organization estimates that almost 800,000 neonatal deaths occur each year from acute respiratory infections, mostly pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/3\">",
"     3",
"    </a>",
"    ]. In a rural area in central India, for example, mortality secondary to pneumonia in the first month was 29 per 1000 live births; more than one-half of all pneumonia deaths in children occurred in newborns [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/4\">",
"     4",
"    </a>",
"    ]. These figures may be an underestimate because many newborns do not receive medical care.",
"   </p>",
"   <p>",
"    In developed countries, the estimated incidence of pneumonia in full-term infants is less than 1 percent. However, among ill infants of normal and low-birth-weight, the incidence may be closer to 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By contrast at autopsy, the incidence of neonatal pneumonia ranges from 20 to 32 percent of live-born and from 15 to 38 percent of stillborn infants, although the pathologic features of inflammation of the lung may not always result from infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/6\">",
"     6",
"    </a>",
"    ]. In one series, infection was the most common etiology of death in extremely low-birth-weight infants (56 of 111); congenital pneumonia accounted for 30 of these 56 infections [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/7\">",
"     7",
"    </a>",
"    ]. Pneumonia caused by maternal enteric organisms frequently accompanies chorioamnionitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    funisitis in these congenital infections.",
"   </p>",
"   <p>",
"    The pathogenesis, clinical manifestations, diagnosis, and treatment of neonatal pneumonia are reviewed here. Neonatal sepsis and specific pathogens are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6410?source=see_link\">",
"     \"Clinical features and diagnosis of sepsis in term and late preterm infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal pneumonia can have early or late onset. Bacteria are the principal pathogens for both types. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Microbiology'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Routes of acquisition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The route of acquisition varies in part with the time of onset of the pneumonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Early-onset pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early-onset pneumonia, generally within three days of birth, is acquired from the mother by one of three routes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intrauterine aspiration of infected amniotic fluid",
"     </li>",
"     <li>",
"      Transplacental transmission of organisms from the mother to the fetus through the placental circulation",
"     </li>",
"     <li>",
"      Aspiration during or after birth of infected amniotic fluid. The neonate can aspirate vaginal organisms, leading to respiratory colonization and, in some cases, pneumonia. Vaginal colonization with such organisms as group B streptococcus (GBS) does not necessarily result in overt maternal infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Late-onset pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late-onset pneumonia, which occurs during hospitalization or after discharge, generally arises from organisms colonizing the hospitalized newborn or is nosocomially acquired from infected individuals or contaminated equipment. Microorganisms can invade through injured tracheal or bronchial mucosa or through the bloodstream.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Mechanism of injury in GBS pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In GBS pneumonia, the level of beta-hemolysin expression appears to correlate directly with the ability of the organism to injure lung epithelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Studies suggest the hemolysin acts as a pore-forming cytolysin. The injury results in increased permeability that contributes to the development of alveolar edema and hemorrhage. This mechanism also may be partially responsible for bloodstream extension. Because surfactant phospholipid inhibits beta-hemolysin-associated lung epithelial cell injury, premature infants who are deficient in surfactant may be more severely affected [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathologic changes vary with the type of organism: bacterial or viral. Bacterial pneumonia is characterized by inflammation of the pleura, infiltration or destruction of bronchopulmonary tissue, and leukocyte and fibrinous exudate within alveoli and the",
"    <span class=\"nowrap\">",
"     bronchi/bronchioles",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Bacteria often are seen within the interstitial spaces, alveoli, and",
"    <span class=\"nowrap\">",
"     bronchi/bronchioles",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Viruses typically cause an interstitial pneumonia. The pneumonia induced by rubella, for example, is characterized by infiltration of mononuclear cells and lymphocytes. Extensive inflammation occasionally occurs with hyaline membrane formation, followed by varying degrees of interstitial fibrosis and scarring [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial, viral, spirochetal, protozoan, and fungal pathogens can cause pneumonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Early-onset pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial pathogens are the most common cause of early- and late-onset pneumonia, although the specific organisms may differ (",
"    <a class=\"graphic graphic_table graphicRef81323 \" href=\"UTD.htm?13/46/14061\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Bacterial infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most early-onset pneumonia is caused by aerobic bacteria, although anaerobes such as Bacteroides sp. occasionally are recovered. GBS causes most early-onset pneumonia in the United States and other developed countries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9621?source=see_link\">",
"     \"Group B streptococcus: Virulence factors and pathogenic mechanisms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18698?source=see_link&amp;anchor=H14#H14\">",
"     \"Group B streptococcal infection in neonates and young infants\", section on 'Pneumonia'",
"    </a>",
"    .) In one study from the United Kingdom of 35 infants with early-onset pneumonia, GBS was responsible for 57 percent of the cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/15\">",
"     15",
"    </a>",
"    ]. Different organisms may predominate in other locations, especially developing countries [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/2,5,16,17\">",
"     2,5,16,17",
"    </a>",
"    ]. In a review of neonatal pneumonia in developing countries, pathogens responsible for early onset neonatal sepsis and pneumonia included Escherichia coli, group B Streptococcus, Klebsiella spp, Staphylococcus aureus, and Streptococcus pneumoniae [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other less common bacterial pathogens include Listeria monocytogenes and Mycobacterium tuberculosis, both of which can be transmitted transplacentally. Although transplacental infection by M. tuberculosis often results in primary liver involvement, pneumonia may be the sole manifestation or may accompany hepatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/18\">",
"     18",
"    </a>",
"    ]. Tuberculosis (TB) occurs with greater frequency in human immunodeficiency virus (HIV)-infected patients, and congenital TB also has become more common [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Possible link of Ureaplasma urealyticum to chronic lung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;One bacterial pathogen, Ureaplasma urealyticum, has been linked potentially to the development of acute and chronic lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/20-24\">",
"     20-24",
"    </a>",
"    ]. This connection has been shown in both small series and a meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 47 infants weighing &lt;1500 g, radiographic features of pneumonia were more frequent within seven days in those colonized with U. urealyticum than in noncolonized infants (53 versus 21 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/20\">",
"       20",
"      </a>",
"      ]. Evidence of \"precocious\" chronic lung disease by radiography also was more common in patients with a positive culture for the organism (23 versus 2 percent). Infants with a positive U. urealyticum culture had a relative risk of 11.0 (95% CI 1.6 -75.5) for oxygen dependence at 36 postmenstrual weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another report, tracheal aspirates were obtained prior to administration of surfactant or antibiotics from 105 very low-birth-weight infants who required mechanical ventilation before 12 hours of age [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/22\">",
"       22",
"      </a>",
"      ]. Infants positive for U. urealyticum were more likely to have chronic lung disease at 28 days but not at 36 postmenstrual weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The efficacy of antimicrobial therapy is uncertain. Two small trials of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"     erythromycin",
"    </a>",
"    therapy in colonized infants failed to show an effect on the development of chronic lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. In addition, there are data to suggest that some isolates of Ureaplasma are not susceptible to erythromycin [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Viral infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herpes simplex virus (HSV) is the most common viral agent to cause early-onset pneumonia, usually following acquisition from the mother at the time of birth [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/27\">",
"     27",
"    </a>",
"    ]. HSV pneumonia occurs in 33 to 54 percent of disseminated HSV infections and usually is fatal in spite of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35321?source=see_link&amp;anchor=H9#H9\">",
"     \"Neonatal herpes simplex virus infection: Clinical features and diagnosis\", section on 'Disseminated disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other viruses can cause pneumonia, usually via transplacental transmission from a mother who acquires the infection late in pregnancy. Examples include adenovirus, enteroviruses, and mumps [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. Interstitial pneumonitis also frequently occurs in congenital rubella infection, although this is an uncommon manifestation of congenital cytomegalovirus (CMV) infection, occurring in less than 1 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Fungal infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candida sp. and other fungal pathogens also are responsible for neonatal pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. In one prospective study, approximately 25 percent of very low-birth-weight infants were colonized by Candida in the gastrointestinal and respiratory tracts, presumably during labor and delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/35\">",
"     35",
"    </a>",
"    ]. Pneumonia occurs in approximately 70 percent of infants with systemic candidiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Other pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasionally, early-onset pneumonia is seen in patients with congenital toxoplasmosis and syphilis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Late-onset pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hospitalized infants often are colonized with organisms that are different from normal flora and that can cause late-onset pneumonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Bacterial infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited information on the bacterial etiology for community acquired, late onset pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/2\">",
"     2",
"    </a>",
"    ]. There appears to be a predominance of gram positive bacteria including S. pyogenes, S. aureus, and S. pneumoniae. Other bacterial pathogens have been implicated in late-onset pneumonia; some of which have characteristic features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Staphylococcus aureus and Klebsiella pneumoniae are notable for inducing extensive tissue damage, abscess formation, and empyema [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      These and other pathogens (eg, Escherichia coli, Serratia marcescens, Enterobacter cloacae, Streptococcus pneumoniae, and Pseudomonas aeruginosa) may cause pneumatoceles [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/39-41\">",
"       39-41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Citrobacter diversus, frequently associated with brain abscesses in neonates, can also cause lung abscess [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bacillus cereus has been associated with necrotizing pneumonia in preterm infants [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/42\">",
"       42",
"      </a>",
"      ] and with pneumonia secondary to contaminated ventilator circuits [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chlamydia trachomatis has a long incubation period and typically is associated with pneumonia occurring between two and four weeks of age [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/44\">",
"       44",
"      </a>",
"      ]. A possible association between early lung disease and a positive tracheal culture for C. trachomatis has been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/45\">",
"       45",
"      </a>",
"      ]. In developing countries where untreated sexually transmitted disease is common, C. trachomatis nasal carriage rate is between 15 to 20 percent and is a risk factor for pneumonia [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/2,16,46\">",
"       2,16,46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Viral infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous viruses, including adenovirus, parainfluenza, rhinovirus, enteroviruses, influenza, and respiratory syncytial virus (RSV), cause pneumonia in the neonatal period [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/28,47,48\">",
"     28,47,48",
"    </a>",
"    ]. Most infants initially are healthy but have ill family members. In a series of 40 newborns with viral pneumonia, nine were born at less than 37 weeks gestation, and RSV accounted for 55 percent of the cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/47\">",
"     47",
"    </a>",
"    ]. RSV is most prevalent during the winter months and results in significant morbidity and mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Fungal infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candida sp. occasionally cause late-onset pneumonia, particularly in extremely low-birth-weight infants who have received prolonged antibiotic therapy and have respiratory tract colonization [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/5,49-51\">",
"     5,49-51",
"    </a>",
"    ]. Corticosteroid administration may increase the risk of systemic infection from Candida sp. in premature infants [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/52,53\">",
"     52,53",
"    </a>",
"    ], potentially increasing the risk of pneumonia.",
"   </p>",
"   <p>",
"    A rare cause of pneumonia is aspergillosis which frequently is fatal [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/54\">",
"     54",
"    </a>",
"    ]. Aspergillus infection can occur in clusters, particularly during hospital renovations [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors associated with early-onset pneumonia include prolonged rupture of the fetal membranes (&gt;18 hours), maternal amnionitis, premature delivery, fetal tachycardia, and maternal intrapartum fever [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/28,56\">",
"     28,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infants who require assisted ventilation are at highest risk for late-onset pneumonia. Data from adults, which are thought to be applicable to neonates, suggest that the risk of nosocomial pneumonia is approximately four times higher in intubated than in nonintubated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/57\">",
"     57",
"    </a>",
"    ]. Other risk factors include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anomalies of the airway (eg, choanal atresia, tracheoesophageal fistula, and cystic adenomatoid malformations)",
"     </li>",
"     <li>",
"      Severe underlying disease",
"     </li>",
"     <li>",
"      Prolonged hospitalization",
"     </li>",
"     <li>",
"      Neurologic impairment resulting in aspiration of gastrointestinal contents.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nosocomial infections occasionally are traced to poor handwashing or overcrowding [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early-onset pneumonia commonly presents with respiratory distress beginning at or soon after birth. Infants may have associated lethargy, apnea, tachycardia and poor perfusion, sometimes progressing to septic shock. Some infants develop pulmonary hypertension. Other signs include temperature instability, metabolic acidosis, and abdominal distension. None of these signs is specific for pneumonia, and respiratory distress also can be caused by noninfectious causes (",
"    <a class=\"graphic graphic_table graphicRef56457 \" href=\"UTD.htm?26/15/26876\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Late-onset pneumonia is marked by changes in the overall condition of the newborn and can include nonspecific signs of apnea, tachypnea, poor feeding, abdominal distention, jaundice, emesis, respiratory distress, and circulatory collapse. Ventilator-dependent infants may have increased oxygen and ventilator requirements or purulent tracheal secretions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because signs of pneumonia are nonspecific, any newborn infant with sudden onset of respiratory distress or other signs of illness should be evaluated for pneumonia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sepsis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cultures of blood and cerebrospinal fluid should be obtained. Pleural fluid, if present in a sufficient volume, can be cultured. If viral or other nonbacterial infection is suspected, specific studies should be obtained including polymerase chain reaction (PCR). Gram stain and culture of tracheal aspirates may identify the causative organism [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/59-61\">",
"     59-61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surveillance tracheal aspirate cultures may provide early information about possible pathogens when sepsis occurs, and diagnosing pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. Needle aspiration or bronchoscopy is difficult to perform in sick newborns and may have significant morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Chest radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chest radiograph can confirm the clinical diagnosis of pneumonia. Bilateral alveolar densities with air bronchograms are characteristic [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/65\">",
"     65",
"    </a>",
"    ], but irregular patchy infiltrates or occasionally a normal pattern also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/66\">",
"     66",
"    </a>",
"    ]. Pneumonia caused by GBS or other pathogens is difficult to distinguish from respiratory distress syndrome in premature infants [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. The presence of pleural effusions may be helpful because they occur in up to 67 percent of patients with pneumonia but are rarely found in respiratory distress syndrome. However, pleural effusions also can be seen in patients with transient tachypnea of the newborn, congenital heart disease, hydrops fetalis, and congenital lymphangiectasia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful treatment depends upon the pathogen, early recognition of the infection, and early therapy prior to the development of irreversible injury.",
"   </p>",
"   <p>",
"    Depending on the severity of respiratory distress, initial management may include oxygen supplementation and mechanical ventilation, in addition to empirical antibiotic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31511?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of neonatal respiratory distress: Disorders of transition\", section on 'Initial management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Bacterial infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of empiric regimens is based upon whether the infection is early- or late-onset.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Early-onset pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;For early-onset pneumonia (age less than three to five days), empiric parenteral antibiotic treatment for maternal genital organisms is started until culture results are available. Once a specific organism is identified, therapy is modified according to the susceptibility pattern.",
"   </p>",
"   <p>",
"    A frequently used initial regimen for empiric coverage is",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"     ampicillin",
"    </a>",
"    (150",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV Q12h if meningitis is suspected and 50 to 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV Q12h if not) and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    (dose based upon gestational age and renal function). Ampicillin is effective against group B streptococcus, most other strains of streptococci, L. monocytogenes, and some Gram-negative bacteria. Ampicillin plus gentamicin also has synergistic activity against many of these organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/70\">",
"     70",
"    </a>",
"    ]. In communities in which a substantial proportion of Gram-negative bacilli are resistant to gentamicin, another aminoglycoside should be substituted.",
"   </p>",
"   <p>",
"    Third generation cephalosporins, although active against many Gram-negative organisms, should not be used for suspected sepsis or pneumonia. Gram-negative bacilli can rapidly develop resistance to cephalosporins by either inducible or chromosomally mediated beta-lactamase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/70,71\">",
"     70,71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Late-onset pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of empiric therapy for late-onset pneumonia depends upon the prevalence and sensitivity of bacteria in both the community and the hospital. For term infants more than three to five days old,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day IV given in divided doses Q8-12h) plus an aminoglycoside (dose based upon age and renal function) is used as initial therapy because of the high prevalence of staphylococcal species resistant to penicillins (eg, Staphylococcus epidermidis and methicillin-resistant S. aureus [MRSA]). Because of the emergence of vancomycin-resistant enterococci (VRE) and S. aureus with reduced susceptibility to vancomycin, vancomycin should be continued only if there is no alternative [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/72\">",
"     72",
"    </a>",
"    ]. Dosing of vancomycin and aminoglycoside in the preterm infant should be determined by postnatal and gestational age.",
"   </p>",
"   <p>",
"    If P. aeruginosa is suspected, an aminoglycoside plus ticarcillin with clavulanate is appropriate therapy (dose is based upon the ticarcillin component at 75 to 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose ticarcillin component administered every 8 to 12 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/70\">",
"     70",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/39/22129?source=see_link\">",
"     Tobramycin",
"    </a>",
"    is particularly active against this organism. Tobramycin dosing is based upon the patient's gestational age and renal function.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/4/14405?source=see_link\">",
"     Ceftazidime",
"    </a>",
"    is an alternative to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/6/35941?source=see_link\">",
"     ticarcillin-clavulanate",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The duration of therapy is guided by the infecting pathogen and the response of the patient. The usual treatment course for uncomplicated pneumonia is 10 to 14 days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Viral infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific agents for the treatment of viral pneumonia are limited. For most viral infections acquired in the perinatal or postnatal period, therapy remains supportive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Herpes simplex virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;If herpes simplex virus (HSV) pneumonia is suspected, intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    (60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in 3 divided doses for 21 days) is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/73\">",
"     73",
"    </a>",
"    ]. HSV pneumonia usually is fatal despite treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35321?source=see_link&amp;anchor=H9#H9\">",
"     \"Neonatal herpes simplex virus infection: Clinical features and diagnosis\", section on 'Disseminated disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Respiratory syncytial virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/59/12216?source=see_link\">",
"     Ribavirin",
"    </a>",
"    is the only available treatment for RSV pneumonia, although trials lack sufficient power to estimate effects reliably. A meta-analysis of randomized trials of ribavirin in infants less than six months old showed that ribavirin reduced the duration of ventilation by 1.2 days (95% CI -0.2 to -3.4) but did not reduce mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21512/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High-risk infants (eg, those with chronic lung disease or born at less than 35 weeks gestation) can receive preventive treatment for RSV. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/17/15640?source=see_link&amp;anchor=H104278870#H104278870\">",
"     \"Respiratory syncytial virus infection: Prevention\", section on 'Target groups for palivizumab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most neonates in developed countries do well, prognosis from neonatal pneumonia is predicated upon the severity of the disease, the gestational age of the patient, underlying medical conditions, and the infecting organism. Increased mortality is associated with preterm birth, pre-existing chronic lung disease, or immune deficiencies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2128161\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumonia is an important cause of neonatal infection and accounts for significant morbidity and mortality.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of neonatal pneumonia varies throughout the world. In developed countries, the estimated incidence of pneumonia in full-term infants is less than 1 percent and increases to 10 percent in preterm infants. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neonatal pneumonia can be classified by the infant's age as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Early-onset pneumonia (&le;3 days), which is generally acquired from the mother during labor or delivery. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Early-onset pneumonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Late-onset pneumonia (&gt;3 days of age), which develops during hospitalization or after discharge by organisms acquired nosocomially from individuals or contaminated equipment, or colonization of the infant. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Late-onset pneumonia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bacterial pneumonia is characterized by inflammation of the pleura, infiltration or destruction of bronchopulmonary tissue, and leukocyte and fibrinous exudate within alveoli and the",
"      <span class=\"nowrap\">",
"       bronchi/bronchioles.",
"      </span>",
"      Viruses cause an interstitial pneumonia, which is often characterized by infiltration of mononuclear cells and lymphocytes. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early-onset bacterial pneumonia is generally caused by group B streptococcus. There are a large number of viral, bacterial, and fungal pathogens that cause neonatal pneumonia. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors associated with early-onset pneumonia include prolonged rupture of the fetal membranes (&gt;18 hours), maternal amnionitis, premature delivery, fetal tachycardia, and maternal intrapartum fever. Late-onset disease is associated with mechanical ventilation, airway anomalies, prolonged hospitalization, and aspiration of gastrointestinal contents due to neurologic impairment. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early-onset pneumonia commonly presents with respiratory distress beginning at or soon after birth. Other clinical manifestations, also seen in late-onset disease, are nonspecific and include temperature instability, apnea, lethargy, tachycardia, poor perfusion, tachypnea, and poor feeding. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radiographic findings, although nonspecific, can establish the diagnosis of neonatal pneumonia, particularly if a pleural effusion is present. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Term and late preterm infants with pneumonia should be treated with empirical antibiotic therapy that provides broad coverage for the most likely pathogens in this age group and the clinical setting. When results of microbiologic tests are available, antibiotic therapy is directed toward the specific pathogen. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although most neonates in developed countries do well, prognosis from neonatal pneumonia is predicated upon the severity of the disease, the gestational age of the patient, underlying medical conditions, and the infecting organism. Increased mortality is associated with preterm birth, pre-existing chronic lung disease, or immune deficiencies. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/1\">",
"      Stoll BJ. The global impact of neonatal infection. Clin Perinatol 1997; 24:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/2\">",
"      Duke T. Neonatal pneumonia in developing countries. Arch Dis Child Fetal Neonatal Ed 2005; 90:F211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/3\">",
"      Garenne M, Ronsmans C, Campbell H. The magnitude of mortality from acute respiratory infections in children under 5 years in developing countries. World Health Stat Q 1992; 45:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/4\">",
"      Bang AT, Bang RA, Morankar VP, et al. Pneumonia in neonates: can it be managed in the community? Arch Dis Child 1993; 68:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/5\">",
"      Dennehy PH. Respiratory infections in the newborn. Clin Perinatol 1987; 14:667.",
"     </a>",
"    </li>",
"    <li>",
"     Barnett ED, Klein, JO. Bacterial Infections of the Respiratory Tract. In: Infectious Diseases of the Fetus and the Newborn, 7th, Remington, JS, et al. (Eds), Elsevier Saunders, Philadelphia 2010. p.276.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/7\">",
"      Barton L, Hodgman JE, Pavlova Z. Causes of death in the extremely low birth weight infant. Pediatrics 1999; 103:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/8\">",
"      Nizet V, Gibson RL, Rubens CE. The role of group B streptococci beta-hemolysin expression in newborn lung injury. Adv Exp Med Biol 1997; 418:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/9\">",
"      Gibson RL, Nizet V, Rubens CE. Group B streptococcal beta-hemolysin promotes injury of lung microvascular endothelial cells. Pediatr Res 1999; 45:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/10\">",
"      DAVIES PA, AHERNE W. Congenital pneumonia. Arch Dis Child 1962; 37:598.",
"     </a>",
"    </li>",
"    <li>",
"     Robbins, SL. The Respiratory System &ndash; Lung. In: Textbook of Pathology With Clinical Application, WB Saunders, Philadelphia 1962. p.562.",
"    </li>",
"    <li>",
"     Hanshaw, JB, Dudgeon, JA. Rubella. In: Viral Diseases of the Fetus and Newborn, WB Saunders, Philadelphia 1978. p.17.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/13\">",
"      Singer DB, Rudolph AJ, Rosenberg HS, et al. Pathology of the congenital rubella syndrome. J Pediatr 1967; 71:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/14\">",
"      Korones, SB, Ainger, LE, Monif, GR, et al. Congenital rubella syndrome: New clinical aspects with recovery of virus from affected infants. J Pediatr 1965; 67:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/15\">",
"      Webber S, Wilkinson AR, Lindsell D, et al. Neonatal pneumonia. Arch Dis Child 1990; 65:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/16\">",
"      Muhe L, Tilahun M, Lulseged S, et al. Etiology of pneumonia, sepsis and meningitis in infants younger than three months of age in Ethiopia. Pediatr Infect Dis J 1999; 18:S56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/17\">",
"      Prasertsom W, Horpaopan S, Ratrisawadi V, et al. Early versus late onset neonatal septicemia at Children's Hospital. J Med Assoc Thai 1990; 73:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/18\">",
"      Starke JR. Tuberculosis. An old disease but a new threat to the mother, fetus, and neonate. Clin Perinatol 1997; 24:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/19\">",
"      Adhikari M, Pillay T, Pillay DG. Tuberculosis in the newborn: an emerging disease. Pediatr Infect Dis J 1997; 16:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/20\">",
"      Pacifico L, Panero A, Roggini M, et al. Ureaplasma urealyticum and pulmonary outcome in a neonatal intensive care population. Pediatr Infect Dis J 1997; 16:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/21\">",
"      Wang EE, Ohlsson A, Kellner JD. Association of Ureaplasma urealyticum colonization with chronic lung disease of prematurity: results of a metaanalysis. J Pediatr 1995; 127:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/22\">",
"      Perzigian RW, Adams JT, Weiner GM, et al. Ureaplasma urealyticum and chronic lung disease in very low birth weight infants during the exogenous surfactant era. Pediatr Infect Dis J 1998; 17:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/23\">",
"      Lyon AJ, McColm J, Middlemist L, et al. Randomised trial of erythromycin on the development of chronic lung disease in preterm infants. Arch Dis Child Fetal Neonatal Ed 1998; 78:F10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/24\">",
"      Bowman ED, Dharmalingam A, Fan WQ, et al. Impact of erythromycin on respiratory colonization of Ureaplasma urealyticum and the development of chronic lung disease in extremely low birth weight infants. Pediatr Infect Dis J 1998; 17:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/25\">",
"      Waites KB, Crouse DT, Cassell GH. Antibiotic susceptibilities and therapeutic options for Ureaplasma urealyticum infections in neonates. Pediatr Infect Dis J 1992; 11:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/26\">",
"      Walls SA, Kong L, Leeming HA, et al. Antibiotic prophylaxis improves Ureaplasma-associated lung disease in suckling mice. Pediatr Res 2009; 66:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/27\">",
"      Barker JA, McLean SD, Jordan GD, et al. Primary neonatal herpes simplex virus pneumonia. Pediatr Infect Dis J 1990; 9:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/28\">",
"      Campbell JR. Neonatal pneumonia. Semin Respir Infect 1996; 11:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/29\">",
"      Meyer K, Girgis N, McGravey V. Adenovirus associated with congenital pleural effusion. J Pediatr 1985; 107:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/30\">",
"      Groenendaal F, Rothbarth PH, van den Anker JN, Spritzer R. Congenital mumps pneumonia: a rare cause of neonatal respiratory distress. Acta Paediatr Scand 1990; 79:1252.",
"     </a>",
"    </li>",
"    <li>",
"     Stagno, S. Cytomegalovirus. In: Infectious Diseases of the Fetus &amp; Newborn, Remington, JS, Klein, JO (Eds), WB Saunders, Philadelphia, 1995, p. 312.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/32\">",
"      Boppana SB, Fowler KB, Britt WJ, et al. Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus. Pediatrics 1999; 104:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/33\">",
"      Ng PC, Siu YK, Lewindon PJ, et al. Congenital Candida pneumonia in a preterm infant. J Paediatr Child Health 1994; 30:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/34\">",
"      Gerberding KM, Eisenhut CC, Engle WA, Cohen MD. Congenital candida pneumonia and sepsis: a case report and review of the literature. J Perinatol 1989; 9:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/35\">",
"      Baley JE, Kliegman RM, Boxerbaum B, Fanaroff AA. Fungal colonization in the very low birth weight infant. Pediatrics 1986; 78:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/36\">",
"      Baley JE, Kliegman RM, Fanaroff AA. Disseminated fungal infections in very low-birth-weight infants: clinical manifestations and epidemiology. Pediatrics 1984; 73:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/37\">",
"      Edell DS, Davidson JJ, Mulvihill DM, Majure M. A common presentation of an uncommon cause of neonatal respiratory distress: pneumonia alba. Pediatr Pulmonol 1993; 15:376.",
"     </a>",
"    </li>",
"    <li>",
"     Marks, MI, Klein, JO. In: Infectious Diseases of the Fetus &amp; Newborn, Remington, JS, Klein, JO (Eds), W B Saunders Company, Philadelphia 1995. p.899.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/39\">",
"      Shamir R, Horev G, Merlob P, Nutman J. Citrobacter diversus lung abscess in a preterm infant. Pediatr Infect Dis J 1990; 9:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/40\">",
"      Khan EA, Wafelman LS, Garcia-Prats JA, Taber LH. Serratia marcescens pneumonia, empyema and pneumatocele in a preterm neonate. Pediatr Infect Dis J 1997; 16:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/41\">",
"      Glustein JZ, Kaplan M. Enterobacter cloacae causing pneumatocele in a neonate. Acta Paediatr 1994; 83:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/42\">",
"      Jevon GP, Dunne WM Jr, Hicks MJ, Langston C. Bacillus cereus pneumonia in premature neonates: a report of two cases. Pediatr Infect Dis J 1993; 12:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/43\">",
"      Gray J, George RH, Durbin GM, et al. An outbreak of Bacillus cereus respiratory tract infections on a neonatal unit due to contaminated ventilator circuits. J Hosp Infect 1999; 41:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/44\">",
"      Jain S. Perinatally acquired Chlamydia trachomatis associated morbidity in young infants. J Matern Fetal Med 1999; 8:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/45\">",
"      Colarizi P, Chiesa C, Pacifico L, et al. Chlamydia trachomatis-associated respiratory disease in the very early neonatal period. Acta Paediatr 1996; 85:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/46\">",
"      Lehmann D, Sanders RC, Marjen B, et al. High rates of Chlamydia trachomatis infections in young Papua New Guinean infants. Pediatr Infect Dis J 1999; 18:S62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/47\">",
"      Abzug MJ, Beam AC, Gyorkos EA, Levin MJ. Viral pneumonia in the first month of life. Pediatr Infect Dis J 1990; 9:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/48\">",
"      Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998; 102:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/49\">",
"      Rowen JL, Rench MA, Kozinetz CA, et al. Endotracheal colonization with Candida enhances risk of systemic candidiasis in very low birth weight neonates. J Pediatr 1994; 124:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/50\">",
"      Loke HL, Verber I, Szymonowicz W, Yu VY. Systemic candidiasis and pneumonia in preterm infants. Aust Paediatr J 1988; 24:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/51\">",
"      Narang A, Agrawal PB, Chakrabarti A, Kumar P. Epidemiology of systemic candidiasis in a tertiary care neonatal unit. J Trop Pediatr 1998; 44:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/52\">",
"      Groll AH, Jaeger G, Allendorf A, et al. Invasive pulmonary aspergillosis in a critically ill neonate: case report and review of invasive aspergillosis during the first 3 months of life. Clin Infect Dis 1998; 27:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/53\">",
"      Botas CM, Kurlat I, Young SM, Sola A. Disseminated candidal infections and intravenous hydrocortisone in preterm infants. Pediatrics 1995; 95:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/54\">",
"      Rowen JL, Atkins JT, Levy ML, et al. Invasive fungal dermatitis in the &lt; or = 1000-gram neonate. Pediatrics 1995; 95:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/55\">",
"      Krasinski K, Holzman RS, Hanna B, et al. Nosocomial fungal infection during hospital renovation. Infect Control 1985; 6:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/56\">",
"      Spaans WA, Knox AJ, Koya HB, Mantell CD. Risk factors for neonatal infection. Aust N Z J Obstet Gynaecol 1990; 30:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/57\">",
"      Cross AS, Roup B. Role of respiratory assistance devices in endemic nosocomial pneumonia. Am J Med 1981; 70:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/58\">",
"      Harbarth S, Sudre P, Dharan S, et al. Outbreak of Enterobacter cloacae related to understaffing, overcrowding, and poor hygiene practices. Infect Control Hosp Epidemiol 1999; 20:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/59\">",
"      Sherman MP, Goetzman BW, Ahlfors CE, Wennberg RP. Tracheal asiration and its clinical correlates in the diagnosis of congenital pneumonia. Pediatrics 1980; 65:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/60\">",
"      Brook I, Martin WJ, Finegold SM. Bacteriology of tracheal aspirates in intubated newborn. Chest 1980; 78:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/61\">",
"      Katayama Y, Minami H, Enomoto M, et al. Usefulness of Gram staining of tracheal aspirates in initial therapy for ventilator-associated pneumonia in extremely preterm neonates. J Perinatol 2010; 30:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/62\">",
"      Jolley AE. The value of surveillance cultures on neonatal intensive care units. J Hosp Infect 1993; 25:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/63\">",
"      Lau YL, Hey E. Sensitivity and specificity of daily tracheal aspirate cultures in predicting organisms causing bacteremia in ventilated neonates. Pediatr Infect Dis J 1991; 10:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/64\">",
"      Booth GR, Al-Hosni M, Ali A, Keenan WJ. The utility of tracheal aspirate cultures in the immediate neonatal period. J Perinatol 2009; 29:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/65\">",
"      Haney PJ, Bohlman M, Sun CC. Radiographic findings in neonatal pneumonia. AJR Am J Roentgenol 1984; 143:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/66\">",
"      Cleveland RH. A radiologic update on medical diseases of the newborn chest. Pediatr Radiol 1995; 25:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/67\">",
"      Hemming VG, McCloskey DW, Hill HR. Pneumonia in the neonate associated with group B streptococcal septicemia. Am J Dis Child 1976; 130:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/68\">",
"      Speer M, Rosan RC, Rudolph AJ. Hemophilus influenzae infection in the neonate mimicking respiratory distress syndrome. J Pediatr 1978; 93:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/69\">",
"      Bortolussi R, Thompson TR, Ferrieri P. Early-onset pneumococcal sepsis in newborn infants. Pediatrics 1977; 60:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/70\">",
"      Edwards MS. Antibacterial therapy in pregnancy and neonates. Clin Perinatol 1997; 24:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/71\">",
"      Gustaferro CA, Steckelberg JM. Cephalosporin antimicrobial agents and related compounds. Mayo Clin Proc 1991; 66:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/72\">",
"      Perl TM. The threat of vancomycin resistance. Am J Med 1999; 106:26S.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Herpes simplex. In: Red Book: 2012  Report of the Committee on Infectious Diseases, 29th, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2009. p.398.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21512/abstract/74\">",
"      Randolph AG, Wang EE. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract. Cochrane Database Syst Rev 2000; :CD000181.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5004 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-853D91569B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_0_21512=[""].join("\n");
var outline_f21_0_21512=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2128161\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Routes of acquisition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Early-onset pneumonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Late-onset pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Mechanism of injury in GBS pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Early-onset pneumonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Bacterial infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Possible link of Ureaplasma urealyticum to chronic lung disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Viral infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Fungal infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Other pathogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Late-onset pneumonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Bacterial infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Viral infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Fungal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Cultures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Chest radiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Bacterial infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Early-onset pneumonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Late-onset pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Viral infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Herpes simplex virus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Respiratory syncytial virus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2128161\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5004\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5004|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/46/14061\" title=\"table 1\">",
"      Causes of neonatal pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/15/26876\" title=\"table 2\">",
"      Noninfectious causes of RD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6410?source=related_link\">",
"      Clinical features and diagnosis of sepsis in term and late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18698?source=related_link\">",
"      Group B streptococcal infection in neonates and young infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9621?source=related_link\">",
"      Group B streptococcus: Virulence factors and pathogenic mechanisms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35321?source=related_link\">",
"      Neonatal herpes simplex virus infection: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31511?source=related_link\">",
"      Overview of neonatal respiratory distress: Disorders of transition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/17/15640?source=related_link\">",
"      Respiratory syncytial virus infection: Prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_0_21513="Transducer position for parasternal short axis view base";
var content_f21_0_21513=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54326%7ECARD%2F66915&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54326%7ECARD%2F66915&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transducer position for obtaining the parasternal short axis view through the base of the heart",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 331px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the upper diagram, the transducer is place at the base of the heart; ie, 2nd intercostal space to the left of the sternum; the plane runs from the right hip to the left shoulder. The portion of the heart labeled RV is actually the right ventricular outflow tract (RVOT). The lower panels show the echocardiographic images which are centered on the pulmonary artery, one of the most important targets for examination. In panel A, the pulmonary artery (MPA) is of normal caliber and two of the three leaflets of the pulmonary valve are seen (PV). Note that the RVOT narrows when it reaches the PV ring, that the bifurcation (Bi) of the MPA can be seen and that in normal anatomy the aortic root (Ao) and MPA differ slightly in caliber (MPA&gt;AO). In panel B, the MPA is dilated due to chronic pulmonary hypertension; the relation of the MPA to the Ao differs sharply from the normal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transducer position for obtaining the parasternal short axis view of the heart",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 358px; height: 342px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown is the transducer position and beam plane used for two-dimensional imaging of the heart in the short axis. In this view the plane of the cut runs through or just below the minor axis of the left ventricle.",
"    <div class=\"footnotes\">",
"     IW: inferior or diaphragmatic wall of the left ventricle; PW: posterior wall of the ventricle; S: interventricular septum; PM: papillary muscles; PMPM: posteromedial; ALPM: anterolateral.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_0_21513=[""].join("\n");
var outline_f21_0_21513=null;
var title_f21_0_21514="Acute otitis media in children: Treatment";
var content_f21_0_21514=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute otitis media in children: Treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/0/21514/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/0/21514/contributors\">",
"     Jerome O Klein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/0/21514/contributors\">",
"     Stephen Pelton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/0/21514/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/0/21514/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/0/21514/contributors\">",
"     Ellen M Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/0/21514/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/0/21514/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/0/21514/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute otitis media (AOM) is the most frequent diagnosis in sick children visiting clinicians' offices in the United States. In 2000, it was estimated that annual expenditures for the diagnosis of otitis media totaled approximately $5 billion in the United States; 40 percent of these costs were for care of children between the ages of one and three years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/1\">",
"     1",
"    </a>",
"    ]. Analysis of data from a 1992 national survey indicated that 30 percent of all antibiotic prescriptions for children were for otitis media [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With rising rates of antimicrobial resistance, the diagnosis and management of AOM have received considerable attention [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. A decrease in overall antibiotic prescriptions for children 15 years and younger was documented between 1989-1990 and 1999-2000 (838 versus 503 per 1000 children) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/5\">",
"     5",
"    </a>",
"    ]. However, the per-visit rates of prescribing antibiotics for otitis media did not change (809 versus 802 per 1000 visits). Antibiotic prescription rates for acute respiratory tract infections declined between 1995 and 2006, but the decline was proportional to the decline in visits for AOM; 80 percent of children diagnosed with AOM received an antibiotic at initial visit [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of AOM will be reviewed here. The epidemiology, pathogenesis, diagnosis, complications, and prevention of AOM are discussed separately, as is chronic otitis media. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=see_link\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42857?source=see_link\">",
"     \"Acute otitis media in children: Prevention of recurrence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22153?source=see_link\">",
"     \"Otitis media with effusion (serous otitis media) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The systemic and local signs and symptoms of acute otitis media (AOM) usually resolve in 24 to 72 hours with appropriate antimicrobial therapy, and somewhat more slowly in children who are not treated initially with antibiotic therapy. Regardless, persistence of middle ear effusion (MEE) after the resolution of acute symptoms is common. In one study, MEE persisted for weeks to months after the onset of AOM in Boston children, 70 percent of whom still had effusion at two weeks, 40 percent at one month, 20 percent at two months, and 10 percent at three months (",
"    <a class=\"graphic graphic_figure graphicRef81406 \" href=\"UTD.htm?14/47/15101\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/7\">",
"     7",
"    </a>",
"    ]. In another study, the resolution of MEE in 90 children who were being treated for AOM was monitored by daily tympanometry (performed by the parents), and by pneumatic otoscopy every two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/8\">",
"     8",
"    </a>",
"    ]. Among the 75 children who were successfully monitored, 69 percent had resolution of effusion within two weeks; the median time to normal tympanogram was 7.5 days (range 1 to 58 days). The detection of biofilms containing bacterial DNA from pneumococcus,",
"    <em>",
"     Haemophilus",
"    </em>",
"    , and",
"    <em>",
"     Moraxella",
"    </em>",
"    on the middle ear mucosa of children with chronic otitis media suggests that persistent MEE may be a result of persisting biofilm on the middle ear mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MEE is associated with conductive hearing loss. Prolonged presence of middle ear fluid may lead to the mistaken diagnosis of AOM in patients with a subsequent febrile illness resulting from other causes. The clinical features, complications, and management of persistent MEE are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22153?source=see_link\">",
"     \"Otitis media with effusion (serous otitis media) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SYMPTOMATIC THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pain remedies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain is a common feature of acute otitis media (AOM). Guidelines issued in 2004 by the American Academy of Pediatrics (AAP) and the American Academy of Family Physicians (AAFP) state that the management of AOM should include an assessment of pain and treatment if pain is present [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/10\">",
"     10",
"    </a>",
"    ]. A number of agents have been evaluated for the treatment of pain associated with otitis media, as illustrated below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized double-blind study compared the use of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"       ibuprofen",
"      </a>",
"      10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      three times per day and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      three times per day versus placebo in 219 children ages one to six years with AOM who also were treated with antibiotics [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/11\">",
"       11",
"      </a>",
"      ]. There was no significant difference in the appearance of the tympanic membrane after two days of treatment between any of the groups. However, by the second day, fewer children treated with ibuprofen had pain than those treated with placebo (7 versus 25 percent). Only 10 percent of children treated with acetaminophen continued to have pain, but this was not statistically significant compared with placebo.",
"     </li>",
"     <li>",
"      The efficacy of a topical agent, Auralgan&reg; (combination of antipyrine,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/19/11574?source=see_link\">",
"       benzocaine",
"      </a>",
"      , and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/10/26787?source=see_link\">",
"       glycerin",
"      </a>",
"      ), was evaluated in a study of 54 children ages 5 to 19 years who presented to an emergency department with ear pain and AOM [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/12\">",
"       12",
"      </a>",
"      ]. Patients were randomly assigned to treatment with Auralgan&reg; or olive oil placebo instilled into the external auditory canal of the affected ear. Significantly more children in the Auralgan&reg; group reported a 25 percent reduction in ear pain scores at 30 minutes after treatment (96 versus 70 percent). Topical benzocaine preparations should not be used in children younger than two years of age because they may cause methemoglobinemia [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43817?source=see_link&amp;anchor=H44#H44\">",
"       \"Topical anesthetics in children\", section on 'Benzocaine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The application of topical aqueous",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/57/37776?source=see_link\">",
"       lidocaine",
"      </a>",
"      (lignocaine) ear drops compared with saline was evaluated in a study of 63 children (aged 3 to 12 years) with AOM and no evidence of perforation [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/14\">",
"       14",
"      </a>",
"      ]. In this small study, patient-reported pain scores were consistently reduced by at least 25 percent over the first 30 minutes following application, and no adverse effects were reported. Further studies of lidocaine are needed to optimize the dose, as well as identify the duration of pain relief and the effectiveness in younger children.",
"     </li>",
"     <li>",
"      The topical herbal extract Otikon Otic solution was compared with topical anesthetic treatment in a randomized trial of 103 children ages 6 to 18 years with pain associated with AOM [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/15\">",
"       15",
"      </a>",
"      ]. Both groups experienced comparable improvements in pain throughout the three days of the study, but there was no placebo group.",
"     </li>",
"     <li>",
"      Remedies such as distraction, external application of heat or cold, and oil instilled into the external auditory canal have been proposed, but there are no controlled trials that directly address the effectiveness of these remedies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Decongestants and antihistamines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of the efficacy of antihistamines and decongestants in treating AOM suggest a lack of benefit and a potential for delayed resolution of middle ear fluid. A 2007 systematic review found that decongestants and antihistamines alone or in combination were associated with increased medication side effects and did not improve healing or prevent surgery or other complications in AOM [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/16\">",
"     16",
"    </a>",
"    ]. In addition, treatment with antihistamines may prolong the duration of middle ear effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/17\">",
"     17",
"    </a>",
"    ]. In children with AOM and known or suspected nasal allergy, an oral decongestant or antihistamine may provide symptomatic relief for nasal congestion. When treating such children, practitioners should weigh the potential symptomatic benefit against the reported adverse events and potential for prolongation of middle ear effusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=see_link&amp;anchor=H25107530#H25107530\">",
"     \"Pharmacotherapy of allergic rhinitis\", section on 'Approach to specific patient groups'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The AAP recommends that over-the-counter cough and cold medications",
"    <strong>",
"     should not",
"    </strong>",
"    be given to infants and children younger than two years of age, due to the risk of life-threatening side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13146?source=see_link&amp;anchor=H199065570#H199065570\">",
"     \"The common cold in children: Treatment and prevention\", section on 'Symptomatic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ANTIBIOTIC THERAPY VERSUS OBSERVATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Academy of Pediatrics (AAP) and American Academy of Family Physicians (AAFP) 2004 guideline suggests that observation without use of antibacterial therapy is an option for selected children with uncomplicated acute otitis media (AOM) based upon diagnostic certainty, age, illness severity, and assurance of follow-up (",
"    <a class=\"graphic graphic_table graphicRef56725 \" href=\"UTD.htm?10/18/10540\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/10\">",
"     10",
"    </a>",
"    ]. A meta-analysis attempted to define which children benefit most from antibiotic therapy for AOM [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/19\">",
"     19",
"    </a>",
"    ]. Children younger than two years, children with bilateral AOM, and children with otorrhea who were treated with antibiotics had the largest differences in outcome compared with similar children who received only symptomatic treatment compared with initial observation. Two subsequent randomized trials, one in the US and one in Finland, confirmed that signs and symptoms of AOM resolved more quickly in children and the risk of perforation with otorrhea is reduced in those initially treated with antibiotics compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Therefore:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that children younger than six months who meet the criteria for a diagnosis of AOM be treated with an appropriate antimicrobial agent.",
"     </li>",
"     <li>",
"      We suggest that children six months to two years who meet the criteria for AOM be treated with an appropriate antimicrobial agent.",
"     </li>",
"     <li>",
"      We suggest that children older than two years who have bilateral disease or otorrhea are best managed with antimicrobial therapy. For those who are normal hosts and who have mild symptoms and signs of unilateral AOM, the watchful waiting option with follow-up may be appropriate when the caretakers understand the risks and benefits of such an approach.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Background",
"    </span>",
"    &nbsp;&mdash;&nbsp;Investigators in the Netherlands were the first to suggest that observation, rather than immediate treatment, might be appropriate for the management of AOM in children. Guidelines from the Dutch College of General Practitioners published in 1990 and revised in 1999 recommended observation for 72 hours for all patients with AOM, and treatment after that time period only for those who are failing to improve [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there are data to suggest that children with \"severe\" AOM and children younger than two years with AOM benefit from antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/23-27\">",
"     23-27",
"    </a>",
"    ]. Consequently, the",
"    <span class=\"nowrap\">",
"     AAP/AAFP",
"    </span>",
"    2004 guideline adopted a modification of the Dutch approach that takes into account the age of the child, the certainty of the diagnosis, and the severity of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/10\">",
"     10",
"    </a>",
"    ]. All children younger than two years of age with a certain diagnosis of AOM and all children with \"severe\" illness (moderate to severe otalgia or fever &ge;39&ordm;C in the previous 24 hours) are treated immediately. Two randomized trials have confirmed the benefit of antimicrobial therapy for children younger than two years of age with AOM [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The option to observe is reserved for children older than two years with certain diagnosis and non-severe illness or uncertain diagnosis (",
"    <a class=\"graphic graphic_table graphicRef56725 \" href=\"UTD.htm?10/18/10540\">",
"     table 1",
"    </a>",
"    ). This guideline suggesting that selected children with AOM can be observed rather than treated immediately represents a departure from previous AAP guidelines recommending antibiotics in all cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Evidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several meta-analyses suggest that many children with AOM do well, even without antibiotic therapy, and that the benefits of antibiotics are modest [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/28,30-32\">",
"     28,30-32",
"    </a>",
"    ]. However, a number of problems with the design of the studies included in the meta-analyses raise troubling issues for interpretation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. The design issues include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Failure to adopt a stringent definition of AOM, resulting in misdiagnosis or inclusion of patients with otitis media with effusion, who usually have sterile middle ear cultures. Patients with otitis media with effusion would not be expected to improve because of antibiotics.",
"     </li>",
"     <li>",
"      Inclusion of patients who were afebrile or had symptoms of mild disease, limiting the apparent benefit of antimicrobial therapy.",
"     </li>",
"     <li>",
"      Exclusion or limited inclusion of patients younger than two years, a group that is generally more difficult to treat.",
"     </li>",
"     <li>",
"      Use of an inappropriate antibiotic or inappropriate dose, resulting in an inadequate comparison between placebo and antibiotic therapy, favoring placebo.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two subsequent randomized trials comparing",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/26/34214?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    and placebo addressed these problems by including only young children (6 to 23 or 35 months); using stringent criteria (a combination of acute",
"    <span class=\"nowrap\">",
"     signs/symptoms",
"    </span>",
"    and middle ear effusion) and experienced otoscopists for diagnosis of AOM; and monitoring clinical and otoscopic outcomes during treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Treatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"     amoxicillin",
"    </a>",
"    -clavulanate was associated with shorter duration of acute signs of illness, fewer treatment failures at the end of treatment (19 versus 45 percent in one study and 16 versus 51 percent in the other), lower rates of residual middle ear effusion at 21 to 25 days (50 versus 63 percent), and increased side effects, predominantly diarrhea (48 versus 27 percent in one study and 25 versus 15 percent in the other). Treatment did not affect the rate of relapse at or before the 21- to 25-day observation period (16 versus 19 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized trials comparing immediate versus delayed antibiotics have used different outcome measures (eg, parental satisfaction, rate of filled prescriptions, etc) and types of follow-up (eg, telephone versus office examination), but also document earlier resolution of symptoms among children who receive immediate treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/37-41\">",
"     37-41",
"    </a>",
"    ]. One of these studies noted an increase in nasopharyngeal carriage of multidrug-resistant",
"    <em>",
"     Streptococcus pneumoniae",
"    </em>",
"    in the group treated with antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of individual patient data from randomized trials attempted to define which children benefit most from antibiotic therapy for AOM [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/19\">",
"     19",
"    </a>",
"    ]. Children with otorrhea and those younger than two years with bilateral otitis media who were treated with antibiotics had the largest differences in outcome compared with similar children who received only symptomatic treatment.",
"   </p>",
"   <p>",
"    Taken together, these studies indicate that some children older than two years of age with AOM can be safely managed initially with observation. Symptoms and signs resolve more rapidly in children with certain diagnoses of AOM who are treated with antibiotics. The concern for antimicrobial resistance underscores the need to use stringent criteria to diagnose AOM [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8760?source=see_link&amp;anchor=H20#H20\">",
"     \"Acute otitis media in children: Diagnosis\", section on 'Clinical diagnosis'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Recommendations of various groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the available data, the",
"    <span class=\"nowrap\">",
"     AAP/AAFP",
"    </span>",
"    2004 guideline suggests that observation without use of antibacterial therapy is an option for selected children with uncomplicated AOM based upon diagnostic certainty, age, illness severity, and assurance of follow-up (",
"    <a class=\"graphic graphic_table graphicRef56725 \" href=\"UTD.htm?10/18/10540\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/10\">",
"     10",
"    </a>",
"    ]. The decision to treat children younger than two years who have a certain diagnosis of AOM that is made according to stringent criteria is supported by randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. For children older than two years of age, clinicians can share with parents or caregivers that antibacterial therapy prescribed at the first visit may shorten symptoms but that the antibiotic may cause side effects some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     AAP/AAFP",
"    </span>",
"    guideline committee recommends the following criteria for selection of patients for observation versus antibacterial therapy (",
"    <a class=\"graphic graphic_table graphicRef56725 \" href=\"UTD.htm?10/18/10540\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibacterial therapy should be administered to any child younger than the age of six months, regardless of the degree of diagnostic certainty.",
"     </li>",
"     <li>",
"      For children ages six months to two years, antibacterial therapy is recommended when the diagnosis of AOM is certain or if the diagnosis is uncertain, but the illness is severe (moderate to severe otalgia or fever &ge;39&ordm;C in the previous 24 hours). Observation is an option only for children in whom the diagnosis is not certain and illness is not severe.",
"     </li>",
"     <li>",
"      For children older than two years, antibacterial therapy is recommended if the diagnosis is certain and illness is severe. Observation is an option when the diagnosis is certain but illness is not severe, and in patients with an uncertain diagnosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Observation is appropriate only when follow-up can be ensured and antibiotic therapy initiated if symptoms persist or worsen [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/10\">",
"     10",
"    </a>",
"    ]. Adequate follow-up may include a parent-initiated visit or phone contact if symptoms worsen or do not improve at 48 to 72 hours, a scheduled follow-up appointment in 48 to 72 hours, or giving parents an antibiotic prescription that can be filled if illness does not improve in this time frame [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/38,39,42-44\">",
"     38,39,42-44",
"    </a>",
"    ]. Antibiotics should be prescribed when the patient does not improve with observation for 48 to 72 hours.",
"   </p>",
"   <p>",
"    Clinicians who recommend initial observation should exercise rigor in diagnosing AOM similar to that in the research protocols that support the safety of this practice. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8760?source=see_link\">",
"     \"Acute otitis media in children: Diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One expert has suggested that more careful attention should be paid to training clinicians to make the diagnosis of AOM properly than to withholding antibiotics for those who meet stringent criteria for AOM [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/33\">",
"     33",
"    </a>",
"    ]. Using this strategy, a similar reduction in the unnecessary use of antibiotics could perhaps be achieved.",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     AAP/AAFP",
"    </span>",
"    2004 guidelines underline the difference in approach to therapy of the child younger or older than two years of age. The older child has fewer episodes of middle ear infection and less severe disease than the infant age group. The differences in disease incidence and severity due to age likely occur because of changes in the anatomy and physiology of the middle ear system and the increase in immune protection against middle ear pathogens. Therefore,",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that children younger than six months who meet the criteria for a diagnosis of AOM be treated with an appropriate antimicrobial agent.",
"     </li>",
"     <li>",
"      We suggest that children six months to two years who have the criteria for AOM be treated with an appropriate antimicrobial agent.",
"     </li>",
"     <li>",
"      We suggest that children older than two years who have bilateral disease or otorrhea are best managed with antimicrobial therapy. For those who are normal hosts and who have mild symptoms and signs of unilateral AOM, the watchful-waiting option with appropriate follow-up may be appropriate when the caretakers understand the risks and benefits of such an approach.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ANTIMICROBIAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the decision is made to treat with antimicrobial agents, the selection of drugs is based upon:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Clinical and microbiologic efficacy",
"     </li>",
"     <li>",
"      Acceptability (taste, texture) of the oral preparation",
"     </li>",
"     <li>",
"      Absence of side effects and toxicity",
"     </li>",
"     <li>",
"      Convenience of the dosing schedule",
"     </li>",
"     <li>",
"      Cost",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Seventeen antimicrobial drugs (16 oral and 1 parenteral preparation) have been approved by the United States Food and Drug Administration (FDA) for the treatment of acute otitis media (AOM) (",
"    <a class=\"graphic graphic_table graphicRef76491 \" href=\"UTD.htm?7/59/8124\">",
"     table 2",
"    </a>",
"    ). In addition, two otic preparations (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/35/37424?source=see_link\">",
"     ofloxacin",
"    </a>",
"    otic and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/11/37042?source=see_link\">",
"     ciprofloxacin-dexamethasone",
"    </a>",
"    otic) also are available for treatment of AOM with otorrhea in children with tympanostomy tubes in place or tympanic membrane perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36457?source=see_link\">",
"     \"Prevention and management of tympanostomy tube otorrhea in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     First-line therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2001 meta-analysis concluded there is no evidence to support any particular antibiotic regimen versus another for treatment of AOM [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/28\">",
"     28",
"    </a>",
"    ]. Nevertheless,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"     amoxicillin",
"    </a>",
"    remains the drug of choice because it is effective, safe, relatively inexpensive, and has a narrow microbiologic spectrum [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/46\">",
"     46",
"    </a>",
"    ]. Doubling the dose from 40 to 80",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day divided into two doses increases the concentration of amoxicillin in the middle ear [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/47\">",
"     47",
"    </a>",
"    ]. The increased concentrations provide activity against most intermediate strains of",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    , as well as many of the resistant strains.",
"   </p>",
"   <p>",
"    The American Academy of Pediatrics (AAP) and American Academy of Family Physicians (AAFP) guideline recommends a dose of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"     amoxicillin",
"    </a>",
"    of 80 to 90",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/10\">",
"     10",
"    </a>",
"    ]. For heavier children, we suggest a maximum dose of 3",
"    <span class=\"nowrap\">",
"     g/day,",
"    </span>",
"    although diarrhea is a potential adverse effect at higher doses. Only",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    that are highly resistant to penicillin will not respond to this regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/48\">",
"     48",
"    </a>",
"    ]. As a result, more than 80 percent of children with pneumococcal AOM would respond to high-dose amoxicillin treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/10\">",
"     10",
"    </a>",
"    ]. Review of data from a large group practice indicates that the proportion of AOM treated with high-dose amoxicillin increased from 1.7 to 41.9 percent between 1996 and 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Treatment failure'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Despite the increasing importance of",
"    <em>",
"     Haemophilus influenzae",
"    </em>",
"    , including beta-lactamase-producing strains, high-dose",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"     amoxicillin",
"    </a>",
"    remains the preferred choice for initial therapy. Continued monitoring of the microbiology of AOM is necessary to determine when and if a change in first-line therapy is necessary. The presence of beta-lactamase negative, ampicillin-resistant strains in the community is potential concern. These strains require minimal inhibitory concentrations of amoxicillin that may be at the upper limit of what is achievable in the middle ear. Such isolates remain uncommon in the US, but have become common in France and Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=see_link&amp;anchor=H17#H17\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\", section on 'Bacteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"     Amoxicillin",
"    </a>",
"    should not be used as first-line therapy in children who are at high risk for AOM caused by an amoxicillin-resistant otopathogen. These include [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/51-54\">",
"     51-54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children who were treated with antibiotics in the previous 30 days, particularly beta-lactam antibiotics",
"     </li>",
"     <li>",
"      Children with concurrent purulent conjunctivitis (otitis-conjunctivitis syndrome usually is caused by nontypeable",
"      <em>",
"       H.",
"      </em>",
"      <em>",
"       influenzae",
"      </em>",
"      , which is frequently resistant to beta-lactam antibiotics)",
"     </li>",
"     <li>",
"      Children receiving",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"       amoxicillin",
"      </a>",
"      for chemoprophylaxis of recurrent AOM (or urinary tract infection) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42857?source=see_link&amp;anchor=H12#H12\">",
"       \"Acute otitis media in children: Prevention of recurrence\", section on 'Antibiotic prophylaxis'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children in the above categories should start therapy with an agent with activity against beta-lactamase-producing nontypeable",
"    <em>",
"     H. influenzae",
"    </em>",
"    , as well as",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    , such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/26/34214?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Treatment failure'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Penicillin allergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acceptable alternatives to penicillin in patients with allergy to penicillin depend upon the type of the previous hypersensitivity reaction (",
"    <a class=\"graphic graphic_table graphicRef80466 \" href=\"UTD.htm?13/11/13500\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link\">",
"     \"Allergy to penicillins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15672?source=see_link\">",
"     \"Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Non-type 1 reactions &ndash; In patients who report penicillin allergy but who did not experience a type 1 hypersensitivity reaction (urticaria or anaphylaxis), we suggest one of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/2/6181?source=see_link\">",
"       Cefdinir",
"      </a>",
"      14",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in 1 or 2 doses; maximum dose 600",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/18/25892?source=see_link\">",
"       Cefpodoxime",
"      </a>",
"      10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day once daily; maximum dose 800",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/61/31701?source=see_link\">",
"       Cefuroxime",
"      </a>",
"      &ndash; cefuroxime axetil suspension: 30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in two divided doses, maximum dose 1",
"      <span class=\"nowrap\">",
"       g/day;",
"      </span>",
"      cefuroxime tablets: 250 mg every 12 hours",
"      <br/>",
"      <br/>",
"      However, these oral agents do not achieve sufficient concentration in the middle ear to eradicate penicillin-resistant",
"      <em>",
"       S. pneumoniae",
"      </em>",
"      .",
"      <br/>",
"      <br/>",
"      A single intramuscular dose of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      provides high concentrations in the middle ear for more than 48 hours and may be considered an alternative for children with AOM and history of non-type 1 penicillin allergy. If clinical signs improve within 48 hours following administration of ceftriaxone, no further therapy is necessary [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/29\">",
"       29",
"      </a>",
"      ]. If clinical signs persist, a second dose is administered and, if necessary, a third dose. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment failure'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type 1 reactions &ndash; Macrolide antibiotics can be used for patients who have had a type 1 hypersensitivity reaction (",
"      <a class=\"graphic graphic_table graphicRef80466 \" href=\"UTD.htm?13/11/13500\">",
"       table 3",
"      </a>",
"      ) to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"       amoxicillin",
"      </a>",
"      or other beta-lactam antimicrobial agents. However, macrolide resistance is common (approximately 25 to 35 percent) among isolates of",
"      <em>",
"       S. pneumoniae",
"      </em>",
"      , and macrolides generally are not effective for eradication of",
"      <em>",
"       H. influenzae",
"      </em>",
"      . Available macrolide drugs approved for AOM include",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"       erythromycin",
"      </a>",
"      plus sulfisoxazole,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"       azithromycin",
"      </a>",
"      , and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"       clarithromycin",
"      </a>",
"      .",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"      (TMP-SMX) should be used with caution because of concern for the presence of resistant pneumococci.",
"      <br/>",
"      <br/>",
"      Erythromycin plus sulfisoxazole 50 to 150",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day of the erythromycin component divided into four doses; maximum dose 2 g erythromycin or 6 g",
"      <span class=\"nowrap\">",
"       sulfisoxazole/day",
"      </span>",
"      may be the most effective of these regimens but is often rejected by patients based upon taste and frequency of dosing [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/55\">",
"       55",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Five days of azithromycin 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day (maximum dose 500",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      as a single dose on day one and 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day (maximum dose 250",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      for days two through five or clarithromycin 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day divided into 2 doses (maximum dose 1",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      can be used, but resistant pneumococcal isolates cannot be overcome by increasing the dose of macrolides, unlike the scenario with beta-lactam drugs [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/46\">",
"       46",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      TMP-SMX may be useful in regions where pneumococcal resistance to TMP-SMX is not a concern. In addition, TMP-SMX should not be used if group A streptococcus (GAS,",
"      <em>",
"       S. pyogenes",
"      </em>",
"      ) is suspected (eg, when there is an associated tympanic membrane perforation). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=see_link&amp;anchor=H29#H29\">",
"       \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\", section on 'TM perforation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most clinical trials and standard pediatric practice provide a 10-day course of an oral antimicrobial agent for the treatment of AOM. However, some data suggest that a shorter course may be adequate [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/56\">",
"     56",
"    </a>",
"    ], and a single dose of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"     azithromycin",
"    </a>",
"    has been approved by the FDA [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/57\">",
"     57",
"    </a>",
"    ]. Unfortunately, many of the studies comparing short- and long-term antibiotic therapy have significant limitations that preclude definitive conclusions.",
"   </p>",
"   <p>",
"    The bulk of data suggests that 10-day therapy is more effective in patients younger than two years and is possibly more effective in children between two and five years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. As a result, the",
"    <span class=\"nowrap\">",
"     AAP/AAFP",
"    </span>",
"    guideline states that a five- to seven-day course of antibiotics is appropriate for children six years and older who have mild to moderate AOM [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/10\">",
"     10",
"    </a>",
"    ]. We suggest that children younger than two years be treated for 10 days and those two years and older without a history of recurrent AOM be treated for five to seven days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Treatment failure",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Definition",
"    </span>",
"    &nbsp;&mdash;&nbsp;With appropriate antimicrobial therapy, the signs of systemic and local illness usually resolve in 24 to 72 hours. Lack of improvement by 48 to 72 hours in a patient treated with antimicrobial therapy suggests either another disease is present or the initial therapy was not adequate. Inadequate therapy is usually related to infection with an organism resistant to beta-lactam antibiotics (nontypeable",
"    <em>",
"     H. influenzae",
"    </em>",
"    and drug-resistant",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    are becoming increasingly important), but infection with less common organisms, such as",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    , also must be considered, particularly in children with tympanostomy tubes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36457?source=see_link&amp;anchor=H11#H11\">",
"     \"Prevention and management of tympanostomy tube otorrhea in children\", section on 'Pathogens'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=see_link&amp;anchor=H16#H16\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fluid may persist in the middle ear for prolonged periods, even when the antimicrobial agents have sterilized the effusion and the acute signs and symptoms are no longer present. Persistent middle ear effusion after the resolution of acute symptoms is not an indication of treatment failure or an indication for additional antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Clinical course'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between bacteriologic and clinical outcomes of culture-positive AOM in young children (3 to 35 months of age) was evaluated in a pooled analysis of 12 studies in which tympanocentesis was performed before and three to five days after initiation of antimicrobial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/64\">",
"     64",
"    </a>",
"    ]. The adjusted relative risk of clinical failure at the end of treatment for patients with bacterial failure versus eradication was 6.5 (95% CI 4.3-10). Clinical failure correlated with bacteriologic failure, regardless of pathogen or treatment regimen.",
"   </p>",
"   <p>",
"    In a similar study, children who had clinical improvement despite bacterial failure developed recurrent AOM more often than those with bacterial eradication (35 versus 24 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/65\">",
"     65",
"    </a>",
"    ]. Most (66 percent) of the recurrences were caused by pathogens present in the initial middle ear fluid sample.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most experts agree on the continued use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"     amoxicillin",
"    </a>",
"    as the drug of choice for the initial treatment of AOM, there is less consensus on the appropriate drug to use when amoxicillin fails. The",
"    <span class=\"nowrap\">",
"     AAP/AAFP",
"    </span>",
"    guideline recommends high-dose",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/26/34214?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    90",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day amoxicillin and 6.4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of clavulanate in two divided doses [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/10\">",
"     10",
"    </a>",
"    ]. The package insert suggests that this dose and formulation may be used for children weighing up to 40 kg, but we suggest a maximum dose of 3 g per day (amoxicillin component). Adolescents &ge;16 years who can take large tablets may use the extended-release formulation 1 g",
"    <span class=\"nowrap\">",
"     amoxicillin/62.5",
"    </span>",
"    mg clavulanate with a dose of 1 to 2 g every 12 hours.",
"   </p>",
"   <p>",
"    Alternatives include most of the drugs listed above for penicillin-allergic patients, including",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/2/6181?source=see_link\">",
"     cefdinir",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/18/25892?source=see_link\">",
"     cefpodoxime",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/61/31701?source=see_link\">",
"     cefuroxime",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    For patients with persistently refractory AOM, tympanocentesis to define the etiology will provide critical information to optimize therapy; tympanocentesis should be performed by an appropriately trained clinician who is comfortable performing the procedure in an awake child (unless there is access to sedation or anesthesia). Alternatively, off-label use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/11/33968?source=see_link\">",
"     levofloxacin",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tympanostomy tube placement may be appropriate [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/63\">",
"     63",
"    </a>",
"    ]. The use of levofloxacin should be reserved for patients with refractory AOM (ideally those who have multidrug-resistant serotype 19A that is susceptible only to levofloxacin and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/52/22345?source=see_link\">",
"     linezolid",
"    </a>",
"    isolated from middle ear fluid). (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Penicillin allergy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Several of these regimens have drawbacks [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/26/34214?source=see_link\">",
"       Amoxicillin-clavulanate",
"      </a>",
"      is advantageous because of efficacy against beta-lactamase-producing",
"      <em>",
"       H. influenzae",
"      </em>",
"      and",
"      <em>",
"       Moraxella catarrhalis",
"      </em>",
"      but has the same efficacy as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"       amoxicillin",
"      </a>",
"      for",
"      <em>",
"       S. pneumoniae",
"      </em>",
"      . Therefore, the value of amoxicillin-clavulanate for treatment failures following use of amoxicillin is restricted to beta-lactamase-producing pathogens.",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/2/6181?source=see_link\">",
"       Cefdinir",
"      </a>",
"      has been suggested as an alternative to amoxicillin-clavulanate [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/61/31701?source=see_link\">",
"       Cefuroxime",
"      </a>",
"      axetil is one of the oral preparations that children may find unpalatable [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/55,67\">",
"       55,67",
"      </a>",
"      ], although its spectrum of activity is excellent for AOM. Because compliance is crucial for eradicating infection, the taste of this preparation is a substantial limitation to its use [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/49/11031?source=see_link\">",
"       erythromycin-sulfisoxazole",
"      </a>",
"      traditionally have been used as a second-line therapy for AOM. However, pneumococcal surveillance studies suggest that resistance to these agents is substantial [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/48,68\">",
"       48,68",
"      </a>",
"      ]. Thus, these agents are not recommended in patients who have failed to improve on",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"       amoxicillin",
"      </a>",
"      . In addition, TMP-SMX should not be used if GAS is suspected (eg, when there is an associated TM perforation). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=see_link&amp;anchor=H29#H29\">",
"       \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\", section on 'TM perforation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Macrolides have limited activity against nontypeable",
"      <em>",
"       H. influenzae",
"      </em>",
"      , which is a more likely pathogen among children who have failed initial",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"       amoxicillin",
"      </a>",
"      therapy; thus, macrolides are not recommended for second-line therapy.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"       Ceftriaxone",
"      </a>",
"      50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IM (maximum dose 1",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      achieves high levels in the middle ear and is effective for the treatment of AOM in children who fail",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"       amoxicillin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/10\">",
"       10",
"      </a>",
"      ]. The controversy over its use arises about how many doses to administer. A single dose of the drug has been the approved treatment of AOM in the United States, but at least one study from Israel showed that three consecutive doses were superior, based upon eradication of penicillin-resistant",
"      <em>",
"       S. pneumoniae",
"      </em>",
"      on follow-up culture of middle ear fluid [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/69\">",
"       69",
"      </a>",
"      ]. One way around this dilemma is to give the first dose and then observe for 48 hours, administering a second or even third dose if clinical symptoms and signs do not respond to the first injection [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/11/33968?source=see_link\">",
"       Levofloxacin",
"      </a>",
"      10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 12 hours by mouth for 10 days for children 6 months to 5 years; 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day by mouth for 10 days for children &ge;5 years (maximum dose 500 to 750",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      was found to be safe and effective for therapy of children with high risk for recurrent or persistent AOM [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/70\">",
"       70",
"      </a>",
"      ]. However, levofloxacin is not FDA approved for the treatment of AOM, and levofloxacin resistance among",
"      <em>",
"       S. pneumoniae",
"      </em>",
"      respiratory isolates has been described in adults [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/71\">",
"       71",
"      </a>",
"      ]. The use of levofloxacin in the treatment of AOM should be reserved for patients with AOM refractory to other drugs (ideally those who have had serotype 19A isolated from the middle ear that is susceptible to levofloxacin) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Tympanocentesis (performed by an appropriately trained clinician) is recommended to make a bacteriologic diagnosis if symptoms persist despite",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    or other broad spectrum therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/63\">",
"     63",
"    </a>",
"    ]. Tympanocentesis should be performed by an appropriately trained clinician who is comfortable performing the procedure in an awake child (unless there is access to sedation or anesthesia).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Recurrent AOM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent AOM is defined by the development of signs and symptoms of AOM (fever, pain, bulging tympanic membrane) soon after completion of successful treatment. It is particularly important to establish the diagnosis with the presence of bulging of the tympanic membrane and signs of inflammation. Otherwise, persistent middle ear effusion in a child with a febrile upper respiratory infection may be misinterpreted as a recurrent episode.",
"   </p>",
"   <p>",
"    There are no randomized trials to guide treatment of recurrent AOM in children. The approach varies depending upon the therapy that was used for recent episodes. It is important to include coverage for resistant pathogens, particularly",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    . When recurrence occurs shortly after completion of antimicrobial treatment for the previous episode (ie, within 30 days), we suggest:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parenteral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for 3 days or possibly every 36 hours (2 doses), or",
"     </li>",
"     <li>",
"      Off-label",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/11/33968?source=see_link\">",
"       levofloxacin",
"      </a>",
"      10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 12 hrs by mouth for 10 days for children six months to five years; 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day by mouth for 10 days for children &ge;5 years (maximum dose 500 to 750",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When the recurrence occurs more than 30 days after completion of the treatment for the previous episode, it is most often due to a different pathogen than the previous episode. Although the child is at higher risk for a nonsusceptible pathogen, we suggest high dose",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/26/34214?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    as initial therapy.",
"   </p>",
"   <p>",
"    Tympanostomy tube insertion may be warranted for children with recurrent AOM. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42857?source=see_link&amp;anchor=H21#H21\">",
"     \"Acute otitis media in children: Prevention of recurrence\", section on 'Tympanostomy tubes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Tympanic membrane perforation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of AOM with acute perforation of the tympanic membrane demonstrate significant benefit from antibiotics. Because of the possibility of GAS, an agent other than",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    should be used. For patients with acute otorrhea, 10 days of oral therapy is more effective than a shorter course [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/72\">",
"     72",
"    </a>",
"    ]. The perforation permits drainage of the middle ear abscess and relieves increased middle ear pressure. With the relief of middle ear pressure, the extensively vascularized tympanic membrane usually heals quickly, sealing the perforation in hours to days.",
"   </p>",
"   <p>",
"    When the perforation occurs in the setting of AOM, topical therapy may be an alternative to oral therapy for the well-appearing, immunocompetent child who is older than two years. However, oral therapy is preferred. Topical therapy with quinolone otic drops (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/35/37424?source=see_link\">",
"     ofloxacin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/15/38128?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ) is equivalent to oral therapy for treatment of otorrhea in children with tympanostomy tubes or chronic suppurative otitis media, but has not been studied in children with AOM and acute perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36457?source=see_link&amp;anchor=H13#H13\">",
"     \"Prevention and management of tympanostomy tube otorrhea in children\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic perforations may occur. A chronically infected middle ear or mastoid may result in persistent suppurative drainage (chronic suppurative otitis media, CSOM). Patients with perforation that persists for three months or longer (with or without suppurative drainage) should be referred to an otolaryngologist for further management [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/75\">",
"     75",
"    </a>",
"    ]. Prevention of CSOM entails prompt and appropriate treatment of acute middle ear infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/76\">",
"     76",
"    </a>",
"    ]. Chemoprophylaxis is not warranted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32743?source=see_link&amp;anchor=H25#H25\">",
"     \"External otitis: Pathogenesis, clinical features, and diagnosis\", section on 'Chronic suppurative otitis media'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If pain occurs or persists in a patient with tympanic membrane perforation, it is important to consider the cause. The pain is unlikely to be due to middle ear infection because the pressure of middle ear fluid is relieved when the tympanic membrane is perforated. Other possible causes include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extension of the infection to a contiguous space, such as the mastoid (ie, mastoiditis) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/16/5385?source=see_link&amp;anchor=H13#H13\">",
"       \"Acute mastoiditis in children: Clinical features and diagnosis\", section on 'Diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16471?source=see_link&amp;anchor=H4#H4\">",
"       \"Acute mastoiditis in children: Treatment and prevention\", section on 'Overview of management'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Irritation of the external canal from middle ear drainage, resulting in otitis externa, in which case treatment with a topical quinolone may be beneficial (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12456?source=see_link&amp;anchor=H279397#H279397\">",
"       \"External otitis: Treatment\", section on 'Topical therapy'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nonantimicrobial topical agents, such as otic antipyrine and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/19/11574?source=see_link\">",
"     benzocaine",
"    </a>",
"    (ie, Auralgan&reg;) or olive oil, should not be used in patients with perforation of the tympanic membrane.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Persistent symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who fail to improve after 48 to 72 hours of antibacterial therapy should be seen in follow-up to confirm the diagnosis of acute otitis media (AOM), evaluate other causes of persistent symptoms, and determine whether a change in antibacterial therapy is warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Treatment failure'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Resolved symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follow-up for children whose symptoms have resolved depends upon the child's age and underlying medical problems, particularly language delay or learning problems. The main reason for follow-up of these children is to monitor the resolution of middle ear effusion (MEE), which is associated with conductive hearing loss and, if chronic, may affect speech, language, and cognitive ability. In addition, prolonged presence of middle ear fluid may lead to the mistaken diagnosis of AOM in patients with a subsequent illnesses resulting from other causes. The management of persistent MEE is discussed separately.",
"   </p>",
"   <p>",
"    Persistent MEE is common after the resolution of acute symptoms. In one study, middle ear effusion persisted for weeks to months after the onset of AOM in Boston children, 70 percent of whom still had effusion at two weeks, 40 percent at one month, 20 percent at two months, and 10 percent at three months (",
"    <a class=\"graphic graphic_figure graphicRef81406 \" href=\"UTD.htm?14/47/15101\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/0/21514/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the prolonged course of resolution of MEE after an episode of AOM, follow-up typically is recommended 8 to 12 weeks after AOM (when 80 to 90 percent of MEE should have resolved). Such follow-up should occur in the following groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All children who are younger than two years; many of these children will already have a routine healthcare visit scheduled within this time frame",
"     </li>",
"     <li>",
"      Children who are older than two years and have language or learning problems also should be seen in follow-up 8 to 12 weeks after AOM",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children older than two years who are without language or learning problems should be followed up at their next health maintenance visit, or sooner if there are concerns regarding persistent hearing loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?43/38/44642?source=see_link\">",
"       \"Patient information: Ear infections (otitis media) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/45/36561?source=see_link\">",
"       \"Patient information: Ruptured eardrum (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/16/15619?source=see_link\">",
"       \"Patient information: Ear infections (otitis media) in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute otitis media (AOM) is the most frequent diagnosis in sick children visiting clinicians' offices in the United States. It accounts for nearly one-third of antibiotic prescriptions written for children. Nearly 80 percent of children diagnosed with AOM receive antibiotics at the initial antibiotics visit. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    With increasing rates of antimicrobial resistance, proper diagnosis of AOM is critical in reducing the unnecessary use of antibiotics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=see_link&amp;anchor=H26#H26\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Persistent middle ear effusion (MEE) is common after the resolution of acute symptoms. It may persist for three months or longer in 10 percent of children. Some investigators have suggested that persistent MEE may be a result of persistent biofilm on the middle ear mucosa. MEE is associated with conductive hearing loss and, if chronic, may affect speech, language, and cognitive ability. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Clinical course'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22153?source=see_link&amp;anchor=H5#H5\">",
"     \"Otitis media with effusion (serous otitis media) in children\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of AOM should involve symptomatic therapy, such as analgesics and antimicrobial therapy, or an observation period of 48 to 72 hours with initiation of antimicrobial therapy for worsening or persistent symptoms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest the use of oral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"       ibuprofen",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      to treat ear pain in children with AOM (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Topical",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/19/11574?source=see_link\">",
"       benzocaine",
"      </a>",
"      preparations are an alternative for children older than two years but should not be used in children younger than two years because of the risk of methemoglobinemia. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pain remedies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend NOT using decongestants",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      antihistamines (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Decongestants and antihistamines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that children with AOM who are younger than six months be treated with antibiotics (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We suggest that children with AOM who are between six months and two years be treated with antibiotics (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). We suggest that children older than two years who have bilateral disease or otorrhea be treated with antimicrobial therapy (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). For those who are normal hosts and who have mild symptoms and signs of unilateral AOM, the watchful waiting option with appropriate follow-up may be appropriate when the caretakers understand the risks and benefits of such an approach. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Antibiotic therapy versus observation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"       amoxicillin",
"      </a>",
"      as the first-line therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Macrolides are an alternative for patients who have had anaphylactic or urticarial reactions to penicillin. However, the prescribing physician should be aware that macrolides lack of activity against most",
"      <em>",
"       Haemophilus influenzae",
"      </em>",
"      isolates and approximately one-third of pneumococcal isolates. Patients with other types of allergic reactions can be treated with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/2/6181?source=see_link\">",
"       cefdinir",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/18/25892?source=see_link\">",
"       cefpodoxime",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/61/31701?source=see_link\">",
"       cefuroxime",
"      </a>",
"      , or intramuscular",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H11\">",
"       'First-line therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that children younger than two years be treated for 10 days and that those two years and older without a history of recurrent AOM be treated for five to seven days (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment failure is defined by lack of symptomatic improvement 48 to 72 hours after initiation of antimicrobial therapy. We suggest that patients who fail first-line therapy be treated with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/26/34214?source=see_link\">",
"       amoxicillin-clavulanate",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Alternatives include",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/2/6181?source=see_link\">",
"       cefdinir",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/18/25892?source=see_link\">",
"       cefpodoxime",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/61/31701?source=see_link\">",
"       cefuroxime",
"      </a>",
"      , and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children younger than two years and children older than two years who have language or learning problems require follow-up at 8 to 12 weeks to monitor the resolution of MEE. Children older than two years who do not have language or learning problems should be followed up at their next health maintenance visit, or sooner if there are concerns regarding persistent hearing loss. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/1\">",
"      Bondy J, Berman S, Glazner J, Lezotte D. Direct expenditures related to otitis media diagnoses: extrapolations from a pediatric medicaid cohort. Pediatrics 2000; 105:E72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/2\">",
"      Nyquist AC, Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for children with colds, upper respiratory tract infections, and bronchitis. JAMA 1998; 279:875.",
"     </a>",
"    </li>",
"    <li>",
"     Bluestone CD, Klein JO. Diagnosis. In: Otitis Media in Infants and Children, 4th ed, BC Decker, Hamilton, ON 2007. p.147.",
"    </li>",
"    <li>",
"     Bluestone CD, Klein JO. Management. In: Otitis Media in Infants and Children, 4th ed, BC Decker, Hamilton, ON 2007. p.213.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/5\">",
"      McCaig LF, Besser RE, Hughes JM. Trends in antimicrobial prescribing rates for children and adolescents. JAMA 2002; 287:3096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/6\">",
"      Grijalva CG, Nuorti JP, Griffin MR. Antibiotic prescription rates for acute respiratory tract infections in US ambulatory settings. JAMA 2009; 302:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/7\">",
"      Teele DW, Klein JO, Rosner BA. Epidemiology of otitis media in children. Ann Otol Rhinol Laryngol Suppl 1980; 89:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/8\">",
"      Renko M, Kontiokari T, Jounio-Ervasti K, et al. Disappearance of middle ear effusion in acute otitis media monitored daily with tympanometry. Acta Paediatr 2006; 95:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/9\">",
"      Hall-Stoodley L, Hu FZ, Gieseke A, et al. Direct detection of bacterial biofilms on the middle-ear mucosa of children with chronic otitis media. JAMA 2006; 296:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/10\">",
"      American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media. Diagnosis and management of acute otitis media. Pediatrics 2004; 113:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/11\">",
"      Bertin L, Pons G, d'Athis P, et al. A randomized, double-blind, multicentre controlled trial of ibuprofen versus acetaminophen and placebo for symptoms of acute otitis media in children. Fundam Clin Pharmacol 1996; 10:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/12\">",
"      Hoberman A, Paradise JL, Reynolds EA, Urkin J. Efficacy of Auralgan for treating ear pain in children with acute otitis media. Arch Pediatr Adolesc Med 1997; 151:675.",
"     </a>",
"    </li>",
"    <li>",
"     Questions &amp; Answers: Reports of a rare, but serious and potentially fatal adverse effect with the use of over-the-counter (OTC) benzocaine gels and liquids applied to the gums or mouth www.fda.gov/Drugs/DrugSafety/ucm250029.htm (Accessed on August 03, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/14\">",
"      Bolt P, Barnett P, Babl FE, Sharwood LN. Topical lignocaine for pain relief in acute otitis media: results of a double-blind placebo-controlled randomised trial. Arch Dis Child 2008; 93:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/15\">",
"      Sarrell EM, Mandelberg A, Cohen HA. Efficacy of naturopathic extracts in the management of ear pain associated with acute otitis media. Arch Pediatr Adolesc Med 2001; 155:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/16\">",
"      Coleman C, Moore M. Decongestants and antihistamines for acute otitis media in children. Cochrane Database Syst Rev 2008; :CD001727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/17\">",
"      Chonmaitree T, Saeed K, Uchida T, et al. A randomized, placebo-controlled trial of the effect of antihistamine or corticosteroid treatment in acute otitis media. J Pediatr 2003; 143:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/18\">",
"      Use of codeine- and dextromethorphan-containing cough remedies in children. American Academy of Pediatrics. Committee on Drugs. Pediatrics 1997; 99:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/19\">",
"      Rovers MM, Glasziou P, Appelman CL, et al. Antibiotics for acute otitis media: a meta-analysis with individual patient data. Lancet 2006; 368:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/20\">",
"      T&auml;htinen PA, Laine MK, Huovinen P, et al. A placebo-controlled trial of antimicrobial treatment for acute otitis media. N Engl J Med 2011; 364:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/21\">",
"      Hoberman A, Paradise JL, Rockette HE, et al. Treatment of acute otitis media in children under 2 years of age. N Engl J Med 2011; 364:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/22\">",
"      Appelman CL, Van Balen FA, van de Lisdonk EH. Otitis media acuta. NHG-standaard. Huisarts Wet 1999; 42:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/23\">",
"      Kaleida PH, Casselbrant ML, Rockette HE, et al. Amoxicillin or myringotomy or both for acute otitis media: results of a randomized clinical trial. Pediatrics 1991; 87:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/24\">",
"      Corbeel L. The \"wait and see\" approach of acute otitis media. Eur J Pediatr 2005; 164:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/25\">",
"      Barry B, Gehanno P, Blumen M, Boucot I. Clinical outcome of acute otitis media caused by pneumococci with decreased susceptibility to penicillin. Scand J Infect Dis 1994; 26:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/26\">",
"      Hotomi M, Yamanaka N, Samukawa T, et al. Treatment and outcome of severe and non-severe acute otitis media. Eur J Pediatr 2005; 164:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/27\">",
"      Rovers MM, Glasziou P, Appelman CL, et al. Predictors of pain and/or fever at 3 to 7 days for children with acute otitis media not treated initially with antibiotics: a meta-analysis of individual patient data. Pediatrics 2007; 119:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/28\">",
"      Takata GS, Chan LS, Shekelle P, et al. Evidence assessment of management of acute otitis media: I. The role of antibiotics in treatment of uncomplicated acute otitis media. Pediatrics 2001; 108:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/29\">",
"      Klein JO. Review of consensus reports on management of acute otitis media. Pediatr Infect Dis J 1999; 18:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/30\">",
"      Glasziou PP, Del Mar CB, Sanders SL, Hayem M. Antibiotics for acute otitis media in children. Cochrane Database Syst Rev 2004; :CD000219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/31\">",
"      Rosenfeld RM, Vertrees JE, Carr J, et al. Clinical efficacy of antimicrobial drugs for acute otitis media: metaanalysis of 5400 children from thirty-three randomized trials. J Pediatr 1994; 124:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/32\">",
"      Coker TR, Chan LS, Newberry SJ, et al. Diagnosis, microbial epidemiology, and antibiotic treatment of acute otitis media in children: a systematic review. JAMA 2010; 304:2161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/33\">",
"      Wald ER. Acute otitis media: more trouble with the evidence. Pediatr Infect Dis J 2003; 22:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/34\">",
"      Wald ER. To treat or not to treat. Pediatrics 2005; 115:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/35\">",
"      Pichichero ME, Casey JR. Diagnostic inaccuracy and subject exclusions render placebo and observational studies of acute otitis media inconclusive. Pediatr Infect Dis J 2008; 27:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/36\">",
"      Klein JO. Is acute otitis media a treatable disease? N Engl J Med 2011; 364:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/37\">",
"      McCormick DP, Chonmaitree T, Pittman C, et al. Nonsevere acute otitis media: a clinical trial comparing outcomes of watchful waiting versus immediate antibiotic treatment. Pediatrics 2005; 115:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/38\">",
"      Spiro DM, Tay KY, Arnold DH, et al. Wait-and-see prescription for the treatment of acute otitis media: a randomized controlled trial. JAMA 2006; 296:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/39\">",
"      Little P, Gould C, Williamson I, et al. Pragmatic randomised controlled trial of two prescribing strategies for childhood acute otitis media. BMJ 2001; 322:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/40\">",
"      Little P, Moore M, Warner G, et al. Longer term outcomes from a randomised trial of prescribing strategies in otitis media. Br J Gen Pract 2006; 56:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/41\">",
"      T&auml;htinen PA, Laine MK, Ruuskanen O, Ruohola A. Delayed versus immediate antimicrobial treatment for acute otitis media. Pediatr Infect Dis J 2012; 31:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/42\">",
"      Cates C. An evidence based approach to reducing antibiotic use in children with acute otitis media: controlled before and after study. BMJ 1999; 318:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/43\">",
"      Siegel RM, Kiely M, Bien JP, et al. Treatment of otitis media with observation and a safety-net antibiotic prescription. Pediatrics 2003; 112:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/44\">",
"      Chao JH, Kunkov S, Reyes LB, et al. Comparison of two approaches to observation therapy for acute otitis media in the emergency department. Pediatrics 2008; 121:e1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/45\">",
"      Goldblatt EL. Efficacy of ofloxacin and other otic preparations for acute otitis media in patients with tympanostomy tubes. Pediatr Infect Dis J 2001; 20:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/46\">",
"      Dowell SF, Butler JC, Giebink GS, et al. Acute otitis media: management and surveillance in an era of pneumococcal resistance--a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J 1999; 18:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/47\">",
"      Seikel K, Shelton S, McCracken GH Jr. Middle ear fluid concentrations of amoxicillin after large dosages in children with acute otitis media. Pediatr Infect Dis J 1997; 16:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/48\">",
"      Jacobs MR, Bajaksouzian S, Zilles A, et al. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study. Antimicrob Agents Chemother 1999; 43:1901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/49\">",
"      Sox CM, Finkelstein JA, Yin R, et al. Trends in otitis media treatment failure and relapse. Pediatrics 2008; 121:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/50\">",
"      Tristram S, Jacobs MR, Appelbaum PC. Antimicrobial resistance in Haemophilus influenzae. Clin Microbiol Rev 2007; 20:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/51\">",
"      Wald ER, Mason EO Jr, Bradley JS, et al. Acute otitis media caused by Streptococcus pneumoniae in children's hospitals between 1994 and 1997. Pediatr Infect Dis J 2001; 20:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/52\">",
"      Kellner JD, Ford-Jones EL. Streptococcus pneumoniae carriage in children attending 59 Canadian child care centers. Toronto Child Care Centre Study Group. Arch Pediatr Adolesc Med 1999; 153:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/53\">",
"      Chung A, Perera R, Brueggemann AB, et al. Effect of antibiotic prescribing on antibiotic resistance in individual children in primary care: prospective cohort study. BMJ 2007; 335:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/54\">",
"      Wroe PC, Lee GM, Finkelstein JA, et al. Pneumococcal carriage and antibiotic resistance in young children before 13-valent conjugate vaccine. Pediatr Infect Dis J 2012; 31:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/55\">",
"      Steele RW, Thomas MP, Begue RE, Despinasse BP. Selection of pediatric antibiotic suspensions: Taste and cost factors. Infect Med 1999; 16:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/56\">",
"      Kozyrskyj A, Klassen TP, Moffatt M, Harvey K. Short-course antibiotics for acute otitis media. Cochrane Database Syst Rev 2010; :CD001095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/57\">",
"      Arguedas A, Loaiza C, Soley C. Single dose azithromycin for the treatment of uncomplicated otitis media. Pediatr Infect Dis J 2004; 23:S108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/58\">",
"      Hoberman A, Paradise JL, Burch DJ, et al. Equivalent efficacy and reduced occurrence of diarrhea from a new formulation of amoxicillin/clavulanate potassium (Augmentin) for treatment of acute otitis media in children. Pediatr Infect Dis J 1997; 16:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/59\">",
"      Cohen R, Levy C, Boucherat M, et al. A multicenter, randomized, double-blind trial of 5 versus 10 days of antibiotic therapy for acute otitis media in young children. J Pediatr 1998; 133:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/60\">",
"      Pessey JJ, Gehanno P, Thoroddsen E, et al. Short course therapy with cefuroxime axetil for acute otitis media: results of a randomized multicenter comparison with amoxicillin/clavulanate. Pediatr Infect Dis J 1999; 18:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/61\">",
"      Al-Shawwa BA, Wegner D. Trimethoprim-sulfamethoxazole plus topical antibiotics as therapy for acute otitis media with otorrhea caused by community-acquired methicillin-resistant Staphylococcus aureus in children. Arch Otolaryngol Head Neck Surg 2005; 131:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/62\">",
"      Santos F, Mankarious LA, Eavey RD. Methicillin-resistant Staphylococcus aureus: pediatric otitis. Arch Otolaryngol Head Neck Surg 2000; 126:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/63\">",
"      Pichichero ME, Casey JR. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA 2007; 298:1772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/64\">",
"      Dagan R, Schneider S, Givon-Lavi N, et al. Failure to achieve early bacterial eradication increases clinical failure rate in acute otitis media in young children. Pediatr Infect Dis J 2008; 27:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/65\">",
"      Asher E, Dagan R, Greenberg D, et al. Persistence of pathogens despite clinical improvement in antibiotic-treated acute otitis media is associated with clinical and bacteriologic relapse. Pediatr Infect Dis J 2008; 27:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/66\">",
"      Block SL, Busman TA, Paris MM, Bukofzer S. Comparison of five-day cefdinir treatment with ten-day low dose amoxicillin/clavulanate treatment for acute otitis media. Pediatr Infect Dis J 2004; 23:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/67\">",
"      Steele RW, Thomas MP, B&eacute;gu&eacute; RE. Compliance issues related to the selection of antibiotic suspensions for children. Pediatr Infect Dis J 2001; 20:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/68\">",
"      Doern GV, Pfaller MA, Kugler K, et al. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis 1998; 27:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/69\">",
"      Leibovitz E, Piglansky L, Raiz S, et al. Bacteriologic and clinical efficacy of one day vs. three day intramuscular ceftriaxone for treatment of nonresponsive acute otitis media in children. Pediatr Infect Dis J 2000; 19:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/70\">",
"      Arguedas A, Dagan R, Pichichero M, et al. An open-label, double tympanocentesis study of levofloxacin therapy in children with, or at high risk for, recurrent or persistent acute otitis media. Pediatr Infect Dis J 2006; 25:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/71\">",
"      Pletz MW, McGee L, Jorgensen J, et al. Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine. Antimicrob Agents Chemother 2004; 48:3491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/72\">",
"      Hendrickse WA, Kusmiesz H, Shelton S, Nelson JD. Five vs. ten days of therapy for acute otitis media. Pediatr Infect Dis J 1988; 7:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/73\">",
"      Goldblatt EL, Dohar J, Nozza RJ, et al. Topical ofloxacin versus systemic amoxicillin/clavulanate in purulent otorrhea in children with tympanostomy tubes. Int J Pediatr Otorhinolaryngol 1998; 46:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/74\">",
"      Suzuki K, Nishimura T, Baba S, et al. Topical ofloxacin for chronic suppurative otitis media and acute exacerbation of chronic otitis media: optimum duration of treatment. Otol Neurotol 2003; 24:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/75\">",
"      Bluestone CD. Clinical course, complications and sequelae of acute otitis media. Pediatr Infect Dis J 2000; 19:S37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/0/21514/abstract/76\">",
"      Bluestone CD. Epidemiology and pathogenesis of chronic suppurative otitis media: implications for prevention and treatment. Int J Pediatr Otorhinolaryngol 1998; 42:207.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5959 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-4C9EBFD82E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_0_21514=[""].join("\n");
var outline_f21_0_21514=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SYMPTOMATIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pain remedies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Decongestants and antihistamines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ANTIBIOTIC THERAPY VERSUS OBSERVATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Background",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Evidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Recommendations of various groups",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ANTIMICROBIAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      First-line therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Penicillin allergy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Treatment failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Definition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Recurrent AOM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Tympanic membrane perforation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Persistent symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Resolved symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5959\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5959|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/47/15101\" title=\"figure 1\">",
"      Persistence of middle ear effusion after AOM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5959|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/18/10540\" title=\"table 1\">",
"      Observation vs antibiotics AOM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/59/8124\" title=\"table 2\">",
"      Antibiotics AOM children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/11/13500\" title=\"table 3\">",
"      Types allergic reactions SS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/16/5385?source=related_link\">",
"      Acute mastoiditis in children: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16471?source=related_link\">",
"      Acute mastoiditis in children: Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8760?source=related_link\">",
"      Acute otitis media in children: Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=related_link\">",
"      Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42857?source=related_link\">",
"      Acute otitis media in children: Prevention of recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=related_link\">",
"      Allergy to penicillins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32743?source=related_link\">",
"      External otitis: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12456?source=related_link\">",
"      External otitis: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22153?source=related_link\">",
"      Otitis media with effusion (serous otitis media) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/38/44642?source=related_link\">",
"      Patient information: Ear infections (otitis media) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/16/15619?source=related_link\">",
"      Patient information: Ear infections (otitis media) in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/45/36561?source=related_link\">",
"      Patient information: Ruptured eardrum (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15672?source=related_link\">",
"      Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=related_link\">",
"      Pharmacotherapy of allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36457?source=related_link\">",
"      Prevention and management of tympanostomy tube otorrhea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13146?source=related_link\">",
"      The common cold in children: Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43817?source=related_link\">",
"      Topical anesthetics in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_0_21515="Indications for paracentesis";
var content_f21_0_21515=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F64189&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F64189&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for abdominal paracentesis in a patient with ascites",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        New onset ascites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        At the time of each admission to the hospital",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Clinical deterioration, either inpatient or outpatient",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Abdominal pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Abdominal tenderness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mental status change",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ileus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypotension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Laboratory abnormalities that may indicate infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Peripheral leukocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Acidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Worsening of renal function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrointestinal bleeding (a high risk time for infection)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_0_21515=[""].join("\n");
var outline_f21_0_21515=null;
var title_f21_0_21516="Causes oligomenorrhea";
var content_f21_0_21516=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F71767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F71767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of oligomenorrhea according to pathophysiology of disorder or condition",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hypothalamic-pituitary axis disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Disorders of weight and/or energy expenditure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Anorexia nervosa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Strenuous exercise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Marked thinness or weight loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Chronic illness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Delayed maturation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central nervous system tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pseudocyesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Ovarian disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Ovarian insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Alkylating antineoplastic agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pelvic irradiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Genetic, syndromic, and autoimmune conditions*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hormone-secreting tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hyperprolactinemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lactation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drugs (see table \"Drugs cause hyperprolactinemia\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pituitary adenoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypothyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hyperandrogenism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polycystic ovary syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adrenal disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Miscellaneous conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hormonal contraception",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypothyroidism or hyperthyroidism",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Eg, Turner syndrome (monosomy, duplication, or mosaicism involving chromosome X), Fragile X associated disorders, autoimmune polyendocrine syndromes. Other causes that are more commonly seen in adult woman are discussed elsewhere (See Nelson, LM. Clinical practice. Primary ovarian insufficiency. N Engl J Med 2009; 360:606.).",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_0_21516=[""].join("\n");
var outline_f21_0_21516=null;
var title_f21_0_21517="O2 consumption during exercise";
var content_f21_0_21517=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oxygen consumption and workload during exercise",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 414px; height: 298px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the normal VO2-workload relationship during incremental exercise to exhaustion (blue circles). The relationship is left-shifted for obese individuals (red triangles).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_0_21517=[""].join("\n");
var outline_f21_0_21517=null;
var title_f21_0_21518="TIMI frame count outcome";
var content_f21_0_21518=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Use of TIMI frame count to risk stratify within TIMI flow grades",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 281px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    TIMI frame count improves risk stratification after a myocardial infarction. Shown is the risk of adverse outcomes assoicated with TIMI flow grades (p = 0.024) and corrected TIMI frame count (p = 0.015) (TFC). The TFC demonstrates that for patients with TIMI grade 2 or 3 flow, in whom the overall risk of an adverse outcome is 27 and 13 percent, respectively, there are lower- and higher-risk subgroups; in those with TIMI grade 3 flow, a TFC &le;20 is associated with a 7.9 percent incidence of an adverse outcome, whereas the incidence with a TFC &gt;20 to &le;40 is 15.5 percent. In patients with TIMI grade 2 flow, the incidence of an adverse outcome ranges from 18.8 to 42.9 percent with TFC of 40 to &gt;100.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Gibson CM, Murphy SA, Rizzo MJ, et al for the TIMI Study Group. Circulation 1999; 99:1945.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_0_21518=[""].join("\n");
var outline_f21_0_21518=null;
var title_f21_0_21519="Lab confirm of LGV";
var content_f21_0_21519=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F50993&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F50993&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Laboratory confirmation of lymphogranuloma venereum (LGV) proctocolitis diagnosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 403px; height: 537px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * For patients with classic LGV symptoms (eg, genital papule or ulcer and inguinal lymphadenopathy) and for patients who are asymptomatic sex partners of LGV case patients, collect urethral (or urine) specimens and test locally for CT. If positive for CT, urethral/urine specimen and serum specimen may be sent to CDC for typing.",
"    </div>",
"    <div class=\"reference\">",
"     Centers for Disease Control and Prevention. Lymphogranuloma Venereum, revised June 19, 2006.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_0_21519=[""].join("\n");
var outline_f21_0_21519=null;
